University of Memphis

University of Memphis Digital Commons
Electronic Theses and Dissertations
2021

Detection of Circulating Biomarkers with Gold-Based
Nanoparticles and Optical Spectroscopy
Raymond E. Wilson

Follow this and additional works at: https://digitalcommons.memphis.edu/etd

Recommended Citation
Wilson, Raymond E., "Detection of Circulating Biomarkers with Gold-Based Nanoparticles and Optical
Spectroscopy" (2021). Electronic Theses and Dissertations. 2841.
https://digitalcommons.memphis.edu/etd/2841

This Dissertation is brought to you for free and open access by University of Memphis Digital Commons. It has
been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of University of
Memphis Digital Commons. For more information, please contact khggerty@memphis.edu.

DETECTION OF CIRCULATING BIOMARKERS WITH GOLD-BASED
NANOPARTICLES AND OPTICAL SPECTROSCOPY

by

Raymond Edward Wilson, Jr.

A Dissertation
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy

Major: Chemistry

The University of Memphis
December 2021

DEDICATION
This dissertation is dedicated to my wife, Thang Pham. She has been a constant support in my
life for over a decade. Thang’s discipline and compassion have always been an inspiration to me,
and I strive to be like her in these ways. She has pushed me throughout graduate school and
encouraged me to overcome every obstacle. I would not be in a position to be completing my
graduate program without her by my side.

ii

ACKNOWLEDGEMENT
Firstly, I would like to express my utmost gratitude for my advisor, Dr. Xiaohua Huang. I
first met Dr. Huang in 2010, when I was an undergraduate research volunteer in her lab. I
became immediately fascinated by the work she was doing, and made an effort to understand the
principles guiding her research. After making the decision to begin graduate school at the
University of Memphis, I had no doubt I would join her lab and begin work right away. During
my time in graduate school, Dr. Huang has taught me so much not only about how to approach
science and experimentation, but also how to communicate, how to treat others, and so much
more. I am incredibly thankful for her patience and support throughout my graduate program.
Secondly, I would like to thank my committee members for their enduring support
throughout my graduate school experience. Each one has a unique set of expertise that has given
me a great deal of insight into my research and allowed me to have a multidisciplinary
perspective of my work. To this end, I would like to thank Dr. Paul Simone, Dr. Yongmei Wang,
Dr. Tomoko Fujiwara, and Dr. Thang Hoang, for the time and effort put forth in guiding me
through my graduate program.
Thirdly, I would like to show my appreciation for my fellow lab members. This includes
Dr. Ryan T. O'Connor and Dr. Elyahb A. Kwizera, both of whom served as mentors to me and
instructed me in countless matters pertaining to our research. I would like to thank Dr. Vojtěch
Vinduška and Zechariah J. Avello, who began graduate school at the same time as me, and were
a constant arm of support for me. I would also like to thank Kristopher D. Amrhein, Alberto
Rodriguez, and Mitchell L. Taylor for their consistent help and friendship which as been a great
aid.

iii

Lastly, I would like to thank the Department of Chemistry at the University of Memphis
for their tremendous support of their graduate students. I am greatly appreciative of the resources
and time they have invested in me. Their support has allowed me to pursue my graduate studies
uninterrupted by financial or other stress. To all of the faculty, staff, and students of this
department, thank you for your continual contribution in making this department function.

iv

PREFACE
The writing of this dissertation is based on three journal articles:
Chapter 1 is designed to give an overview of the role of gold nanoparticles in the
biomedical field with an emphasis on biological detection. Some of their important physical and
chemical qualities are discussed as a basis for their application to biodetection. Further, several
important examples of their use in biodetection are presented for consideration.
Chapter 2 is devoted to an article that was published in the ACS Journal of Applied
Materials and Interfaces: “Wilson Jr, R.E., O’Connor, R., Gallops, C.E., Kwizera, E.A., Noroozi,
B., Morshed, B.I., Wang, Y. and Huang, X. Immunomagnetic capture and multiplexed surface
marker detection of circulating tumor cells with magnetic multicolor surface-enhanced Raman
scattering nanotags. ACS Applied Materials & Interfaces 2020, 12(42), 47220-47232.” The
tables, figures, schematics, and references from this article have been reformatted and
renumbered to agree with this document. The references and style of this chapter fit the standards
prescribed by the Journal of Applied Materials and Interfaces.
Chapter 3 is based on an article “Optimizing Cellular Binding of Ligand-Conjugated
Gold Nanoparticles” that is currently being prepared by its authors.
Chapter 4 is based on an article “Development of a Gold Nanoparticle-Enhanced
Enzyme-Linked Immunosorbent Assay for Detection of SARS-CoV-2 Spike Protein Antibodies”
which is currently in preparation by its authors.
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ABSTRACT
Raymond Edward Wilson, Jr. The University of Memphis. December 2021. Detection of
Circulating Biomarkers with Gold-Based Nanoparticles and Optical Spectroscopy.
Major Professor: Prof. Xiaohua Huang

Gold nanoparticles (AuNPs) are remarkable agents for biological detection due to their
facile surface modification, optical enhancement, and biocompatibility. These characteristics
encourage the development of new methods for biological detection. Of particular interest, in the
field of biological detection, is the ability to detect, quantify, and characterize circulating
biomarkers. Circulating biomarkers include classes of biological analytes such as cells,
extracellular vesicles, proteins, DNAs, and RNAs. The ability to detect and characterize such
analytes gives clinicians two significant advantages in diagnosing diseases. One advantage is
diagnosis by means of a non-invasive biopsy, as circulating biomarkers may be isolated and
detected from a patient’s blood. A second major advantage is earlier detection than what is
provided by a traditional tissue biopsy. For example, many cancers go undetected until the
disease has metastasized, significantly limiting chances of a successful treatment outcome.
However, biomarkers that reflect the molecular contents of the tumor are being released into the
bloodstream, even in early stages of tumorigenesis. Hence, the ability to detect and characterize
such biomarkers would lead to earlier detection and potentially a better treatment outcome. In
this dissertation, we explore the unique properties of AuNPs that enable their use as agents for
circulating biomarker detections. In addition, we highlight recent methods utilizing AuNPs for
biological detection. Next, we report on our method for the isolation, detection and
characterization of circulating tumor cells using core-shell iron oxide-gold nanoparticles (IO-Au
NPs). This method combines magnetic capture, microfluidics, fluorescence and surface enhanced
Raman scattering (SERS) spectroscopy for detection and multicolor characterization of
vi

circulating tumor cells. Additionally, we report on a study to optimize the cellular binding of
ligand-conjugated AuNPs. In this study we undertake a rigorous effort to design ligandconjugated AuNPs that feature high degrees of specificity and reproducibility. Finally, we
demonstrate a method of AuNP-enhanced enzyme-linked immunosorbent assay (ELISA)
designed for detection of antibodies to the spike protein of severe acute respiratory syndrome
coronavirus 2 (SARS‑CoV‑2). Our enhanced ELISA method gives an approximately 100-fold
increase in sensitivity over traditional ELISA methods, and also shares the agility of traditional
ELISA that allows detection of a multitude of analytes.
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Chapter 1. INTRODUCTION
1. History, Synthesis, and Properties of Gold Nanoparticles
1.1 History of Gold Nanoparticles
Gold is a rare and precious metal often associated with coins, jewelry, and other works of
art. It is highly stable in its bulk form and, unlike some metals, is not susceptible to oxidation or
deterioration, leading to its coveted use in sculptures, Olympic medals, and more.2 Gold
nanoparticles (AuNPs) are simply particles composed of gold with an effective diameter in the
range of 1 – 100 nm. Uses for gold colloidal nanoparticles have been around for centuries. In one
of the earliest known examples, the Lycurgus cup was created in the 4th century CE using
AuNPs.3 The Lycurgus cup is an ancient display showcasing AuNPs’ unique optical properties in
the form of dichroic glass, which appears red by transmitted light and appears green by reflected
light.4 Beyond their aesthetic merit, AuNPs are of great practical value due to properties unique
to their size and composition. Scientific inquiry into the nature of AuNPs dates back to at least
the 1850s, when Michael Faraday documented the synthesis of colloidal AuNPs.5 Several years
later, Gustav Mie made an important theoretical discovery when, in 1908, he presented a solution
for Maxwell’s equations of electromagnetism which accurately described the absorption and
scattering spectra of spherical gold nanoparticles.6-9 Advances in controlling the synthesis of
gold nanoparticles continued with the work of Turkevich et al. in 1951 and Frens who, in 1973,
reproducibly synthesized monodisperse spherical gold nanoparticles by using Turkevich’s
citrate-mediated growth procedure.10,11
In the latter part of the 20th century, many important discoveries paved the way for gold
nanoparticles’ use in medical diagnostics. One such discovery was that of surface-enhanced

1

Raman scattering (SERS), which occurred in 1973 when Fleischmann et al. observed the
enhancement of the Raman spectrum of pyridine adsorbed onto a silver electrode.12 Important
efforts soon followed by Van Duyne and Jeanmaire, and separately by Albrecht and Creighton,
to explain the mechanism seen in surface-enhanced Raman scattering.13,14 In 1997, Nie and
Emory published groundbreaking results purporting single molecule and single particle detection
using silver nanoparticles (AgNPs) and SERS.15 This important work demonstrated the potential
of metallic nanoparticles for aiding detection of rare analytes. Near this time, AuNPs entered the
field of biosensing in many different capacities.
One of the early studies pointing to AuNPs’ potential for novel biological detection
occurred in 1996, when it was reported that the reversible aggregation of small oligonucleotidebound AuNPs could be observed while complementary target deoxyribonucleic acids (DNA)
were present.16 Furthermore, these oligonucleotide-bound AuNP aggregates exhibited
extraordinarily sharp melting profiles. Both of these observations were results of unique
properties of AuNPs; namely, a high surface-to-volume ratio and uncommon optical activities.
This work spawned a flurry of research into designing nanomaterials for biological diagnostics
and therapeutics.17 (Figure 1.1) Further developments in the 21st century include the important
work of Hirsch et al., who documented the detection of proteins in serum and whole blood using
antibody-bound gold nanoshells.18 They were able to differentiate the extinction spectra of free
gold nanoshells from the spectra of gold nanoshells bound to target proteins, reporting an analyte
sensitivity below 1 ng/mL which is comparable to ELISA. Another important work occurred in
2006, when Huang et al. demonstrated the therapeutic value of AuNPs in addition to the
diagnostic potential.19 In this report, it is shown that anti-epidermal growth factor receptor
(EGFR) conjugated to gold nanorods (AuNRs) express a high affinity to certain malignant-type
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cells. Furthermore, once the AuNRs were bound to the malignant cells, they readily destroyed
the cancer cells when shown by a near-infrared (NIR) laser, effectively converting the light into
heat.20 These works highlight the important advancements made to create a critical role for
AuNPs in the biomedical field.
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Figure 1.1. The significant growth of research publications regarding AuNPs in the biomedical
sector in the 21st century.1 Publication numbers are generated by a PubMed keyword search of
“gold nanoparticles”, which retrieves articles from the MEDLINE database cataloging works
published in the areas of life science and biomedicine.

1.2 Synthesis Methods for Various Types of Gold Nanoparticles
In the previous section, it was mentioned that Faraday was one of the first scientists to
document the synthesis of AuNPs.5 In his work, he recorded the formation of a red solution of
colloidal AuNPs upon the reduction of a gold salt by phosphorus in the presence of carbon
disulfide. Even to this day, many protocols for synthesizing AuNPs follow a variation of
Faraday’s method, whereby a gold salt is reduced in the presence of a capping agent which helps
to prevent the aggregation of particles.2 The standard modern method for generating colloidal
3

gold nanospheres (AuNS) is performed by the reduction of the tetrachlorate ion (AuCl4-) by
sodium citrate. In this reaction, nanoclusters of 5 nm diameter begin to form and branch into a
network of nanowires.21 As the reaction proceeds, the diameter of the nanowires begins to
increase as more gold is deposited. Eventually the nanowires break into smaller segments which
ultimately give way to a spherical nanoparticle. This reaction may be used to reliably produce
colloidal AuNPs between 5 and 150 nm in diameter by controlling the sodium citrate to gold ion
ratio, the reaction pH, and the solvent.11,22,23 Gold nanospheres are the most basic synthetic shape
of gold nanoparticles, but much effort has gone into designing AuNPs with various sizes and
shapes.
One of the first shapes to be designed beyond the spherical gold nanoparticle was that of
the gold nanorod (AuNR).24,25 In one of their first iterations, AuNRs were generated by
electrochemically depositing gold into the pores of microporous alumina membranes and
dissolving the template membrane. This is an example of a hard template-directed method for
AuNR synthesis, which may be of interest for generating high-purity AuNRs for the study or
effect of higher-order surface plasmon resonances (SPR).26 Another important work in the
development of synthetic AuNRs was the discovery that upon electrochemical
oxidation/reduction of a gold plate anode and platinum plate cathode in the presence of the
cationic surfactant, hexadecyltrimethyl-ammonium bromide (CTAB), and a rod-inducing
cosurfactant, tetraoctylammonium bromide (TOAB), AuNRs approximately 10 nm in diameter
of varying aspect ratios could be discerned.27 In this work, it was shown that two unique SPR
modes occur for AuNRs due to the presence of a short axis (transverse mode) and long axis
(longitudinal mode) of polarization. In the early 21st century, very important developments in the
discovery of methods for the colloidal synthesis of AuNRs occurred.28,29 These studies resulted
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in a seed-mediated AuNR growth method, whereby small gold seeds are first generated upon the
reduction of AuCl4- by borohydride in the presence of CTAB, and later planted into a growth
solution consisting of AuCl4- reduced by ascorbic acid, silver nitrate (AgNO3), and CTAB. The
resulting particles are AuNRs with a rod diameter of 10 – 20 nm and an adjustable rod-length up
to 300 nm. Parameters such as the gold seed/gold salt ratio and the added concentration of ion
impurities may be utilized to vary the aspect ratio in this method. Figure 1.2 demonstrates how
the aspect ratio, and thus the longitudinal SPR band, may be varied upon adding different
amounts of AgNO3. These particles, like other AuNPs, are highly desirable for their tunable
shape-dependent optical properties, leading to their use in a variety of biomedical applications.30
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Figure 1.2. Demonstrating the tunable optical properties of gold nanorods. A) Gold nanorod
solutions with increasing concentrations of silver nitrate from left to right. B) UV-vis absorbance
spectra of gold nanorod solutions with varying concentrations of silver nitrate indicating the
controlled adjustment of the longitudinal surface plasmon band.

AuNPs may be formed in a variety of geometries including gold-silver nanocages, hollow
gold nanoshells, gold nanocubes, gold nanoprisms, and an assortment of other shapes. 31-34
Furthermore, AuNPs may be combined with another element or molecule for multiplex
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nanoparticles. A common platform to deliver this multiplex approach is that of a core-shell
nanoparticle, in which the core of this particle is comprised of one substance, and the shell is
comprised of another. Magnetic-optical core-shell nanoparticles are a particularly useful type of
core-shell particle as they utilize a magnetic core, typically composed of cobalt or iron or a
compound thereof, and a plasmonic shell, usually composed of silver, gold, or platinum.35 This
class of particles has many biomedical applications from magnetic resonance imaging to
photothermal therapy.36-38 A popular core-shell composition consists of an iron oxide
nanoparticle (IO NP) core inside of a gold shell. This is due to the straightforward methods for
synthesis of IO NPs, as well as the tunable optical properties and biocompatibility characteristic
of AuNPs. Core-shell IO-Au NPs may be synthesized by a direct deposition method where IO
NPs are first prepared through the coprecipitation of a ferric chloride and ferrous chloride
mixture under basic conditions. This is followed by the reduction of chloroauric acid by sodium
citrate in the presence of IO NPs at boiling temperature.39-41 In addition to direct deposition
synthesis methods, IO-Au NPs may be created by gold-seeded growth methods, where
electrostatically adsorbed small AuNPs on IO NP surface serve as nucleation sites for the growth
of a gold shell. This may be accomplished by attaching small negatively-charged citrate-capped
AuNPs to positively-charge polyethyleneimine (PEI)-coated IO NPs. This is followed by the
reduction of chloroauric acid by hydroxylamine (NH2OH) in the presence of gold-seeded IO NPs
for gold shell formation.42 A similar method can be used for the synthesis of anisotropic IO-Au
NPs, where citrate-capped AuNPs are electrostatically adsorbed onto the surface of octahedral
PEI-coated IO NPs. Next, Au-seeded IO NPs are planted into a growth solution consisting of
HAuCl4, CTAB, AgNO3, and ascorbic acid.43 By controlling the amount of ascorbic acid, as well
as the presence or absence of AgNO3, IO-Au NPs may be created into the shapes of spheres,
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popcorn, or stars. Anisotropic IO-Au NPs may be desirable for the significant electromagnetic
enhancement they yield compared to sphere-shaped nanoparticles.44 These are a few of many
important methods for creating IO-Au NPs, which combine the magnetic separability of
magnetic nanoparticles with the optical enhancement and ready surface modification of AuNPs.
Based on these properties, IO-Au NPs are a significant asset for the selective isolation and
detection of circulating biomarkers.
1.3 Biological, Chemical, and Physical Properties of AuNPs
In the previous sections, it has been noted that AuNPs possess qualities desired for use in
the biomedical field. One important criterion for biomedical application of AuNPs is
biocompatibility. In one critical study, the potential for cytotoxic and immunogenic effects of
lysine- and poly-L-lysine-capped AuNPs was explored through their effect on RAW264.7
macrophage cells.45 In this case, it was determined that AuNPs are not cytotoxic to cells as
measured by a 3-(4,5-dimethylazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay, which
distinguishes living cells from dead cells.46 Further, AuNPs do not promote an immunogenic
response such as the stress-induced release of tumor necrosis factor alpha (TNFα) and interleukin
1 beta (IL-1β). Interestingly, it was actually shown AuNPs exhibit some therapeutic value by
mitigating the production of reactive oxygen species (ROS) and reactive nitrite species (RNS).
Of course, AuNPs’ biocompatibility must be qualified by a number of parameters including
capping agent and particle concentration.47 Nevertheless, a number of AuNP platforms have been
proven nontoxic and are even positioned for commercial use. Aurimune (CYT-6091), a
polyethylene glycol-coated AuNP developed by Cytimmune, has shown to be safe for effectively
delivering TNFα to tumor sites and is undergoing clinical trials.48 This highlights AuNPs’
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biocompatible character, and distinguishes them from other metallic nanoparticles such as
AgNPs which have been shown to be cytotoxic.49
In addition to biocompatibility, AuNPs are sought after tools for biomedical application
due to their readily modified surface and high surface-to-volume ratio. The high surface area
with respect to the particle volume means efficient packing and delivery of therapeutics, probes,
and biomolecules to a site of interest.50-52 AuNPs also express an amendable surface capable of
attaching to countless ligands, peptides, oligonucleotides, etc. Although AuNPs may be
stabilized by various ligands, dendrimers, polymers, and surfactants, the preferred rout for
modification centers around the strong gold-sulphur (Au-S) bond.53,54 Any functional thiolate
may be introduced to AuNPs to modify the particles’ behavior. In this manner, AuNPs may be
conjugated to antibodies for targeting, polymers for stabilizing, dyes for staining, and many more
applications.
AuNPs also demonstrate a phenomenon unique to nanoscale materials known as
localized surface plasmon resonance (LSPR). This occurs when a metallic nanoparticle is
irradiated by light causing the conducting electrons to oscillate in a coherent fashion.9 This
oscillation is confined to the surface of the nanoparticle and generates an electromagnetic field in
the vicinity of the nanoparticle.55 A direct application of LSPR is for SERS, where a Raman
scattering molecule adsorbed to the particle surface experiences a greatly enhanced local field
upon excitation of the surface plasmon. Experimentally, it has been shown the Raman scattering
signal may be enhanced by up to 1014 – 1015.15 This remarkable enhancement combined with the
sharp, fingerprint-like Raman spectra of Raman scattering molecules leads to methods for
extremely sensitive and selective detection of rare analytes.
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2. Methods for Functionalization of AuNPs
AuNPs often require modification after synthesis to ensure biocompatibility as well as to
designate a function for the particle. The methods for modifying the surface of AuNPs mostly
follow the work accomplished in understanding self-assembled monolayers of molecules on a
gold surface.56,57 There are many molecular linkers that may be attached to AuNPs for future
functionalization, however, these linkers are generally attached to the particle by the same goldreactive functional groups such as amines, carboxylates, thiolates, dithiolates, dithiocarbamates,
etc.53,58-60 The selection of a functional group to anchor molecular linkers depends on the
application, but generally thiolates are selected for attachment of non-labile applications, while
amine and carboxylate functional groups are chosen when labile application is desired. AuNPs
are commonly functionalized to incorporate organic dyes, fluorescent dyes, PEG, amino acids,
peptides, proteins, DNA, and RNA, or a combination thereof. The versatility to which AuNPs
may be functionalized lend their application in a wide variety of biomedical roles.
2.1 PEGylation of AuNPs
For biological applications, it is often imperative that AuNPs be stabilized for protection
against high levels of biomolecules and ions. For this purpose, it is standard for AuNPs to
contain a layer of PEG on their surface. With this modification, PEGylated AuNPs demonstrate
good hydrophilicity for ready diffusion in aqueous media. It has been shown that PEGylated
tamoxifen-targeted AuNPs can be used to treat estrogen receptor positive breast cancer cells with
enhanced drug potency in vitro.61 Due to the effect of enhanced permeability and retention (EPR)
characteristic of stable AuNPs, these PEGylated tamoxifen-targeted AuNPs preferentially
accumulate at the tumor site.62 Furthermore, it has been demonstrated that PEGylated AuNPs
show an enhanced circulatory half-life.63 This is accomplished by the PEG layer shielding the
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AuNPs from circulating proteins and opsonins. In another study, PEGylated AuNPs have shown
to be valuable X-ray contrast agents, overcoming many limitations common to X-ray imaging
such as a short imaging window, renal toxicity, and low contrast in larger patients.64
2.2 AuNPs functionalized by Oligonucleotides
Oligonucleotide-modified AuNPs may demonstrate unique affinity for recognizing
complementary sequences in DNA segments. In one study it was shown that AuNPs modified by
5’- or 3’-mercaptoalkyloligonucleotides showed excellent stability in the presence of high ionic
strength solution (up to 1 M NaCl) and high DNA content (up to 2 mg/mL salmon sperm DNA)
without suffering a decrease in function.65 This work demonstrated the selective and sensitive
detection of oligonucleotide (down to 10 femtomoles) upon the color-changing reaction created
by the interaction between single-stranded target oligonucleotides and the mercaptoalkyloligonucleotide-modified AuNPs. The same group demonstrated the potential of mercaptoalkyloligonucleotide-modified AuNPs for controlled macro-assembly upon interaction of the
oligonucleotide-modified AuNPs with complementary DNA.16 In another study, a unique
anchoring group was discovered for modifying AuNPs to incorporate oligonucleotides, and the
resulting AuNPs were shown to be much more stable in the presence of reducing agents such as
dithiothreitol.66 The anchoring group consists of a cyclic disulfide derived from the condensation
of 4,5-dihydroxy-1,2 dithiane and epiandrosterone and is shown to create much more stable
conjugates than those modified by conventional mercaptohexyl groups or an acyclic disulfide
group. These are some of the popular methods for creating oligonucleotide-modified AuNPs
with applications in nucleotide detection as well as assembly of macro-structures using AuNPs
as building blocks.
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2.3 AuNPs functionalized by Amino Acids, Peptides, and Proteins
AuNPs may be functionalized by proteins or their building blocks for a variety of
applications. AuNPs can be functionalized by amino acid-conjugated thiols to incorporate DNA
for gene delivery.67 By controlling the surface charge density of the amino acid-modified
AuNPs, it is possible to optimize the modified AuNPs for controlled binding and subsequent
condensation of DNA. For attaching peptides and proteins to AuNPs, there have been a number
of covalent and non-covalent strategies deployed. For non-covalent attachment, conjugation of
antibodies to citrate-capped AuNPs has been achieved by electrostatic and hydrophobic
interaction between the antibody and citrate-capped AuNPs.68 For this application, optimum
binding occurs when the pH of antibody and AuNP solution is maintained at or slightly above
the isoelectric point (pI) of the antibody. However, non-covalent attachment of antibodies to
AuNPs does express some limitations such as requiring a large concentration of precious
antibodies as well as randomized orientation of the adsorbed abtibody.69 To address these
concerns, several methods for covalent attachment of proteins to AuNPs have been developed.
One method includes dative binding to form a covalent bond between the protein and the AuNP.
This is made possible by the presence of free sulfhydryl groups on the protein.70 In addition to
dative binding, coupling reactions allow covalent attachment of peptides and proteins to
functional linkers on the AuNP surface. A commonly employed strategy is the carbodiimide
cross-coupling reaction where a carboxylic acid group on a protein is activated by 1-ethyl-3-(-3dimethylaminopropyl) carbodiimide hydrochloride (EDC) to generate an active O-acylisourea
intermediate that will further react with a primary amine-containing linker on the AuNP to form
a covalent bond.71 Furthermore, active ester compounds such as N-hydroxy-succinimide (NHS)
may be used to react with primary amines for covalent amide bond formation.72
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3. Current Applications of AuNPs in Biological Detection
3.1 Metal Ions
The potential for AuNPs to generate colorimetric reactions lends their application for
detection of a wide range of analytes. For metal ions, detection of Pb(II) is critical due to the
health disadvantages of lead exposure.73 One interesting method utilizes AuNPs functionalized
by deoxyribozymes to detect Pb(II).74 Their lead biosensor consists of AuNPs, a deoxyribozyme
and its substrate, and 5‘-thio-modified 12-mer DNA. The substrate was designed to hybridize
specifically with the DNA on AuNP surface, causing aggregation of the AuNPs and the
formation of a blue-colored solution. However, when Pb(II) is present, aggregation is prevented
by the hydrolytic cleavage of the substrate catalyzed by the deoxyribozyme, maintaining a redcolored solution. The detection limit for this sensor can be tuned from 100 nM to 200 µM Pb(II).
A similar strategy has been applied to the detection of lithium ions depending on the
aggregation of AuNPs to generate a colorimetric reaction.75 In this method, AuNPs were
conjugated to a ligand, 2,9-Dibutyl-1,10-phenanthroline-5,6-aminoethanethiol, which forms a
ligand-lithium complex between two ligands and one lithium ion. This complex initiates the
aggregation of AuNPs which exhibit a red-shift in their extinction spectra with increasing lithium
ion concentration. It was demonstrated this method was effective for detecting lithium ions in the
range of 10 to 100 mM.
3.2 Nucleic Acids
Detection of nucleic acids by AuNPs typically rely on the color-changing AuNP
aggregation initiated by DNA hybridization as illustrated in previous sections.16 Another group
reports a rapid, label-free AuNP-based DNA detection method capable of detecting specific
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sequences and single nucleotide polymorphisms with no detection instrumentation necessary and
an assay time reported to be under 10 minutes.76 For non-colorimetric assays, SPR methods may
be employed for ultra-sensitive detection of DNA hybridization.77 In such a study,
oligonucleotide probes were created by the conjugation of AuNPs to thiol-labeled DNA. These
oligonucleotide-conjugated AuNPs were then used to identify target DNA attached to a gold
surface through a sequence-specific hybridization. The presence of AuNPs were found to
drastically amplify the SPR response upon DNA hybridization. The limit of quantitation for this
method was calculated to be 10 pM for 24-mer oligonucleotides. Another application for nucleic
acid detection by AuNPs incorporates the use of molecular beacons. In one study, AuNPs
attached to a DNA with a fluorophore were used to detect specific DNA sequences.78 The
AuNPs in this case served as a scaffold as well as a quencher.
3.3 Proteins
The use of antibody-conjugated AuNPs are a common method for detecting proteins. For
example, a gold nanoshell-based aggregation immunoassay was developed for the detection of
rabbit IgG in saline, bovine serum, and human whole blood.18 The assay involved the use of antirabbit IgG conjugated to gold nanoshells which were subsequently mixed with different IgGcontaining media. The mixture was monitored for changes in the optical extinction at 720 nm,
where a proportional decrease in extinction was discovered to occur with increasing interaction
between the anti-IgG AuNPs and the analyte IgG. Other approaches include a Raman-based
assay with the use of a protein array along with targeted SERS AuNPs.79 This technique is
notable for its use of a protein array to allow multiplex screening of protein-small molecule and
protein-protein interactions. And yet another novel approach for detecting proteins with AuNPs
employs SERS core-shell AuNPs for the separation and detection of multiple proteins.80 In this
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sandwich-based immunoassay, an anti-IgG-coated silver substrate was used to capture analyte.
The samples were then labeled by anti-IgG core-shell AuNPs with a Raman-active molecule
affixed for selective detection of analyte. This method reports a remarkable sensitivity of
detecting down to 800 ag/mL for mouse IgG and a detection limit of 5 fg/mL for human IgG.
3.4 Viruses
Some of the same methods for detection of nucleic acids and proteins can be applied to
viruses. In one study, a method for detection of dengue virus was reported that combines
circulating-flow quartz crystal microbalance analysis with DNA-conjugated AuNPs.81 The
modified AuNPs were used to enhance the sensitivity of the quartz crystal microbalance as well
as to delegate the specificity of DNA hybridization. This proved to be a very sensitive method
detecting down to 2 plaque forming units /ml of dengue virus serotype 2. Another study,
developed a method for detecting human immunodeficiency virus type 1 (HIV-1) involving the
use of an antibody array for viral P24 antigen capture and antibody-conjugated AuNPs to
enhance atomic force microscopy (AFM) measurements.82 This is yet another very sensitive
assay capable of detecting down to 25 fg/mL P24 antigen which is approximately a 1000-fold
increase in sensitivity compared to conventional ELISA.
3.5 Circulating Tumor Cells
Cancer cells can be shed from an original tumor and enter the bloodstream through an
epithelial-mesenchymal transition (EMT) resulting in circulating tumor cells (CTCs). CTCs
highlight the malignant behavior of cancer, playing a major role in metastasis.83 Detection and
molecular characterization of CTCs can facilitate early detection of cancer, help predict
treatment response, and provide new therapeutic targets, all through minimally invasive
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sampling.84,85 Previous work has demonstrated the great potential for using multiplex core-shell
iron oxide-gold nanoparticles (IO-Au NPs) for CTC capture and detection.86 These particles
combine the excellent specificity of immunomagnetic capture with the sensitivity of surfaceenhanced Raman scattering (SERS) spectroscopy. This method showed a limit of detection
(LOD) near 1 CTC in 1 mL of blood. It implemented a one-channel capillary tube through which
IO-Au NP-labelled cancer cells passed. The cells were captured and concentrated by a series of
magnetic fields and analyzed by a portable Raman spectrometer. In addition to sensitivity and
reliability, this method offers significant opportunity for screening multiple cancer markers
simultaneously.
4. Overview of Chapter Contents
In Chapter 2, we will demonstrate our novel method for using multicolor SERS IO-Au
NPs to isolate, detect, and characterize the surface expression of CTCs. In this manner, we are
able to simultaneously measure the expression of four separate cancer cell surface markers. First,
we demonstrate the quality of our antibody-targeted Raman-tagged IO-AuNPs through darkfield
imaging of labeled cancer cells. These functionalized IO-Au NPs show strong affinity and
specificity for their antigen, as well as a strong Raman signal as measured in solution. Next,
cancer cells are spike into various media, and labelled by our functionalized IO-Au NPs. The
labeled cells are then passed through a microfluidic chip in the presence of a magnet for isolation
of the cancer cells. Captured cells are subsequently stained by DAPI and anti-CD45/FITC to
distinguish cancer cells from potential white blood cells, and probed by our Raman spectrometer
to characterize surface marker expression. We conclude that our antibody-targeted Ramantagged IO-AuNPs combine with the microfluidic device provide a fast, sensitive, multicolor
method for detecting CTCs from whole blood.
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In Chapter 3, we seek to optimize the cellular binding of streptavidin-conjugated AuNPs
by observing the effects of ligand density, labeling media, and stabilizing polymer on the
targeted AuNPs. We reproducibly observe the importance of optimizing ligand density by
monitoring the size of streptavidin-conjugated AuNPs with varying ratios of coating density. We
also observe the impact of common biological blocking agents and detergents at different steps
in the cell labeling procedure. Furthermore, we sought to understand the impact of the common
AuNP-stabilizing polymer on particle affinity. In conclusion, we developed detailed protocols
for achieving optimum in vitro cellular binding of ligand-conjugated AuNPs for future
applications.
In Chapter 4, we will take a look at how AuNPs may play role in responding the COVID19 pandemic. We emphasize the importance of serological testing to determine the prevalence of
SARS-CoV-2 as well as to monitor vaccine response. Thus, we develop a method for AuNPenhanced ELISA for detection of SARS-CoV-2 IgG. We use the unique surface properties of
AuNPs to deliver anti-IgG/HRP to spike protein IgG. This method shows promising sensitivity
with up to a 100-fold enhancement over conventional ELISA. We also demonstrate this method
may be deployed for detecting IgG in human blood plasma.
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Chapter 2. IMMUNOMAGNETIC CAPTURE AND MULTIPLEXED SURFACE
MARKER DETECTION OF CIRCULATING TUMOR CELLS WITH MAGNETIC
MULTICOLOR SURFACE-ENHANCED RAMAN SCATERRING NANOTAGS
1. Introduction
Cancer remains a major health problem worldwide.87 Metastasis is the main cause of
death in cancer patients, accounting for 90% of the mortality.88 Circulating tumor cells (CTCs),
the malignant cells of epithelial origin circulating in blood, are the hallmark of metastasis.89−91
Their detection and analysis can provide a powerful tool in the clinic for the diagnosis of
metastasis at an early stage, prognosis of cancer patients, assessment of tumor stage, monitoring
of therapeutic response, and ultimately helping the optimization of personalized treatment.92-95
CTC analysis, however, is very challenging because CTCs are rare events; approximately
one to few CTCs were found to be mixed with about 10 million white blood cells (WBCs) and 5
billion red blood cells in 1 ml of blood of cancer patients.92 To accomplish reliable results, CTC
analysis generally requires a combination of enrichment and detection methods. During the last 2
decades, a variety of techniques have been developed for CTC isolation and detection,96,97
including some commercialized products such as EPISPOT, AdnaTest, and CellSearch, the only
technique that has been approved by the U.S. Food and Drug Administration (FDA) for clinical
applications.98−100
However, most techniques can only detect CTCs of one specific population such as
epithelial cell adhesion molecule (EpCAM)-positive CTCs.101 It is known that CTCs are a
heterogenous population. EpCAM is the most common marker for CTC recognition. However,
EpCAM down-regulation has also been correlated with CTCs in peripheral blood.102 Thus, CTCs
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with low or no EpCAM expression go undetected leading to false negatives. A combination of
EpCAM and other cancer-specific markers is needed to improve the detection accuracy. This
requires a multiplexed approach to recognize and detect CTCs with different surface markers.
Multiplexed detection was usually performed with fluorescence imaging coupled with CTC
separation techniques.103−106 In 2014, Nima reported a multiplexed imaging method based on
surface-enhanced Raman scattering (SERS) mapping.107 In their studies, silver−gold nanorods
were coated with four different Raman reporters to detect four different surface markers with
respective antibodies. Using the signature peak of each Raman reporter, the targeted surface
marker was detected by SERS imaging. Compared to the fluorescence approach, SERS is
advantageous in multiplexed detection because it gives narrow and fingerprint signals, have a
low background, and excellent photostability.
In this work, we present a new multiplexed CTC assay that combines microchip-based
immunomagnetic isolation with multicolor detection using magnetic-optical core−shell SERS
nanotags. We use iron oxide−gold (IO−Au) core−shell SERS nanotags for the dual purpose of
capturing cancer cells via immunomagnetic separation and subsequently detecting them via
SERS spectroscopy in a microfluidic device. By varying the Raman reporter and the target
antibody, we simultaneously capture and quantitatively detect four different surface protein
markers on individual cells. The use of “all-in-one” IO−Au SERS nanotags in combination with
a microfluidic device eliminates cumbersome sample processing and reduces the risk of CTC
loss. Combining immunomagnetic enrichment with high specificity, multiplexed targeting for the
capture of CTC subpopulations, multicolor SERS detection with high sensitivity and specificity,
microfluidics for handling rare tumor cells and magnetic-optical nanoparticles (NPs) for dual
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enrichment and detection, our integrated, yet simple and efficient platform shows strong
potential to more sensitively detect and monitor cancer metastasis.
2. Materials and Methods
2.1 Materials
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise
specified. All antibodies except HER2 from Sigma-Aldrich were purchased from BioLegend
(San Diego, CA). QSY21 carboxylic acid-succinimidyl ester (QYS21- NHS), QXL680, BHQ3COOH, and IR740 were purchased from Fisher Scientific (Waltham, MA), Anaspec (Fremont,
CA), Biosearch Technologies (Dexter, MI), and Sigma-Aldrich, respectively. Isotype IgG was
purchased from Fisher Scientific. Thiolated methoxy polyethylene glycol (mPEG-SH, MW =
5000) and thiolated polyethylene glycol N-hydroxy succinimide (HS-PEG-NHS, MW = 5000)
were purchased from Nanocs (New York, NY). SKBR-3, MDA-MB-231, and MCF-7 breast
cancer cells were purchased from ATCC (Manassas, VA). Dulbecco’s modified Eagle’s medium
(DMEM) with high glucose (4.5 g/L), RPMI 1640 medium, 0.25% trypsin, and 100 U/mL
HyClone penicillin−streptomycin (P/S) were purchased from VWR (Atlanta, GA). Fetal bovine
serum (FBS), nonessential amino acids (NEAA), cell dissociation buffer, goat antimouse IgG
conjugated with horseradish peroxidase (HRP), and bovine serum albumin (BSA) were
purchased from Fisher Scientific (Waltham, MA). Human blood from healthy donors were
purchased from Research Blood Components (Watertown, MA). 4′,6- Diamidino-2-phenylindole
(DAPI), fluorescein isothiocyanate (FITC)-labeled CD45, 1-Step Ultra 3,3′,5,5′tetramethylbenzidine (TMB)-enzyme-linked immunosorbent assay (ELISA) substrate solution,
and Micro BCA reagent were purchased from Thermo Fisher Scientific.
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2.2. Synthesis and Characterization of IO−Au Core−Shell NPs
Popcorn-shaped IO−Au core−shell NPs (IO−Au NPCs) were synthesized following the
seed-mediated growth method developed by us previously.43 Briefly, ferromagnetic octahedral
IO NPs around 35 nm in edge length were synthesized as the core via precipitation of FeSO4 in a
basic solution followed by oxidation in the presence of branched polyethyleneimine (PEI). Then,
the PEI-stabilized IO NPs were coated with small Au NPs (<10 nm) via electrostatic adsorption
to form seed particles. Popcorn IO−Au core−shell NPs were formed by anisotropic growth of the
seed particles in a growth solution containing chloroauric acid, cetyl trimethyl ammonium
bromide, ascorbic acid, and silver nitrate. The size and morphology of the IO core, Au-seeded IO
NPs, and IO−Au NPCs were examined with a JEOL JEM1200EX II transmission electron
microscope. The absorption spectra were collected using a visible−near-infrared (vis-NIR)
absorption spectrometer (Ocean Optics, Dunedin, FL). Magnetic separation was performed with
a Qiagen 12-tube magnet. The concentration of the NPs was determined via NP tracking analysis
using a NanoSight LM10 microscope (Malvern Instruments). The size and zeta potential were
measured by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments).
2.3. Preparation and Characterization of Multicolor IO−Au SERS Nanotags
To prepare IO−Au SERS nanotags, EpCAM, HER2, CD44, or IGF1R antibodies (Abs),
or isotype IgG was functionalized with HS-PEG by incubating the Ab solution (10 μg) with HSPEG-NHS (MW = 5000, Ab/NP = 100 in molar ratio) in phosphate-buffered saline (PBS, pH =
7.4) at 4 °C for 16 h. The thiolated Ab or IgG control was separated from free HS-PEG linkers
by filtration with a centrifugal filter (30 kDa MWCO) (Pall Corporation). The purified HS-PEGAb or IgG control was mixed with 250 μL of 0.5 nM IO−Au NPCs (Ab/NP = 400) for 8 h at
room temperature (RT). Then, Raman reporters (QSY21 for EpCAM, BHQ3 for HER2, QXL680
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for CD44, and IR740 for IGF1R) were added with specific dyes at NP molar ratios (15,000 for
QSY21, 15,000 for QXL680, 45,000 for BHQ3, and 5000 for IR740) and mixed with constant
stirring for 15 min. Then, mPEG-SH (105 /NPC molar ratio) was added and the mixture was
incubated with constant stirring for 45 min at RT. The resulting SERS nanotags were purified by
centrifugation at 10,000 rpm for 10 min, re-dispersed in 250 μL of Dulbecco’s PBS (DPBS), and
stored at 4 °C until use. The size and zeta potential of the SERS nanotags were characterized by
DLS. SERS signals were measured with a portable TSI ProRaman spectrometer (λ = 785 nm).
The TMB assay was performed to confirm the successful conjugation of Ab to IO−Au NPCs by
our conjugation method using HRP as the protein representative. Briefly, 100 μL of HRPconjugated IO−Au NPCs were mixed with 25 μL of 1-Step Ultra TMB-ELISA substrate solution
for 25 min and the color change of the solution was recorded. IO−Au NPCs without HRP was
used as the negative control. The Micro BCA protein assay was used to determine the number of
proteins bound to the NPs using IgG as the model. Briefly, IgG-linked IO−Au NPCs with
various IgG loading ratios were mixed with the Micro BCA reagent with equal molar amounts
and incubated for 60 min at 60 °C. The absorption at 562 nm was measured and compared
against a standard curve of pure IgG solution.
2.4. Cell Culture and Cell Collection
SK-BR-3, MDA-MB-231, and MCF-7 breast cancer cells were cultured in their
respective media (RPMI 1640 for SK-BR-3 and DMEM for MDA-MB-231 and MCF7) with
10% FBS, 1% NEAA, 100 U/mL penicillin, and 0.1 mg/mL streptomycin at 37 °C with 5%
CO2. To collect cells, cells were cultured in a 6-well culture plate at a density of 5 × 104
cells/well and incubated for 48−72 h. Next, cells were washed three times with DPBS and
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incubated in cell dissociation buffer for 10 min at 37 °C. The dislodged cells were centrifuged at
1500 rpm for 5 min and resuspended in DPBS for immediate use.
2.5. Characterization of Cell Surface Protein Expression with a Cellular ELISA
In a typical assay, 2000 cells per well (in 50 μL medium) were plated in a 96-well cell
culture plate and incubated for 24−48 h at 37 °C with 5% CO2. Following a wash with PBST
(PBS with 0.1% Tween 20 Detergent), cells were fixed in 50 μL of 1% paraformaldehyde for 12
min at 37 °C. Cells were then washed and nonspecific binding spots were blocked with 100 μL
of 1% BSA for 30 min at 37 °C. After blocking, cells were washed once more and incubated
with 50 μL of 2 μg/mL primary antibody for 1 h at 37 °C. This step was succeeded by three
washes and labeling with 50 μL of 1:60 goat anti-mouse IgG-HRP (in 1% BSA) for 1 h at 37 °C.
Following five more washes, 100 μL of TMB was added to each well and the plate was
incubated at 37 °C for 10 min. After 10 min of incubation, the reaction was stopped with 100 μL
of 2 M sulfuric acid. Finally, the absorbance of each well was measured at 450 nm using a
BioTek ELx800 microplate reader.
2.6. Cellular Binding and SERS Detection of Cancer Cells with IO−Au SERS Nanotags
In a microcentrifuge vial, 100 μL of DPBS containing ∼5 × 104 cells (SK-BR-3, MDAMB-231, or MCF7) and four-color nanotags (each 12.5 pM) or an IgG control nanotag were
incubated for 30 min at 37 °C with intermittent mixing. Following incubation, the labeled cells
were centrifuged and fixed in 1% paraformaldehyde for 15 min at 25 °C. After purification by
centrifugation, the cells were resuspended in DPBS and examined under a dark field using an
Olympus IX71 inverted microscope and measured with a Raman microscope.
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2.7. Fabrication of Microfluidic Device
The microfluidic device was designed with COMSOL Multiphysics software. The chip
contained two transparent quartz slides, each of 4.5 cm length, 1.5 cm width, and 1 mm
thickness, fused together. The top slide contained through-hole fluidic ports (D = 1 mm),
whereas the bottom slide had microfluidic channels with a depth of 100 μm. After fusion, the
microchannel was sandwiched between the two slides with access only through the ports. The
major components of the device were: the isolation and detection chambers (20 mm length × 5
mm width × 0.1 mm thickness), six fluidic ports (A to F), and the connection channels (1 mm
width × 0.1 mm thickness). A cylindrical neodymium−iron− boron (NdFeB) magnet with a
diameter of 20 mm and a thickness of 25 mm was attached to the chip under the chamber to
capture NP-bound CTCs. The six ports were as follows: A is connected to the blood sample inlet,
B supplies PBS to wash the cells after each step, C supplies the fix solution to fix the cells, D
supplies FITC-labeled CD45 monoclonal antibodies to recognize WBC impurities, E supplies
DAPI to counterstain the cell nucleus, and F is the waste outlet. The channel was terminated at
the fluidic ports that were connected to a syringe via capillary and port assemblies. The chamber
held ∼10 μL solution. The dead volume in each side channel will be less than 1 μL. The
microfluidic device was fabricated commercially by Micronit Microfluidics.
2.8. Determination of the Flow Rate for Magnetic Cell Capture in Microfluidic Device
To determine the flow rate that preferentially captures cancer cells over free NPs, SKBR-3 cells were labeled with a cocktail of anti-EpCAM and anti-HER2 IO−Au NPCs, purified
by centrifugation, and fixed with paraformaldehyde using the procedure described above. 1 mL
of 300,000 labeled cells were pumped through the microfluidic chip at a range of flow rates.
Uncaptured cells were collected and counted using a hemocytometer to determine the capture
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efficiency of labeled cells. To determine the capture efficiency of free NPs, 1 mL of 5 pM
mPEG-stabilized IO−Au NPCs were flowed through the microfluidic chip under the presence of
the magnet at various flow velocities and collected at the end. Uncaptured NPs were quantified
by UV−vis absorption spectroscopy. Capture efficiency was calculated as the percentage of
captured cells or NPs over the added amount of cells or NPs.
2.9. Magnetic Capture and SERS Detection of CTCs in the Microfluidic Device
In a microcentrifuge vial, 100 μL of human blood spiked with 1000 breast cancer cells
(SK-BR-3, MDA-MB-231, or MCF-7) were incubated with a cocktail of 4-color nanotags (each
of 12.5 pM final concentration) or an IgG control nanotag for 30 min at 37 °C with intermittent
mixing. Then, the solution was diluted to 1 mL with DPBS and flowed across the microfluidic
device in the presence of the magnet with a flow rate of 50 μL/min, followed by washing with
DPBS. Captured cells were fixed by 1% paraformaldehyde for 10 min. After washing with
DPBS, the cells were stained with 300 nM DAPI for 5 min. After washing with DPBS, captured
cells were labeled with 1 μg/mL FITC antihuman CD45 antibodies for 30 min. After washing,
the cells were examined with an integrated Raman/fluorescence microscope that consists of an
Olympus CX41 fluorescence microscope and a TSI ProRaman L spectrometer with laser
excitation at 785 nm. The SERS spectra on single cells were collected with a 40× objective. The
laser spot size at focus is 30 μm. The laser power is 100 mW and the acquisition time is 10 s.
Fluorescence images were collected with a DAPI filter (λexcitation = 387/11 nm; λemission = 447/60
nm) to visualize cell nuclei and an FITC filter (λexcitation = 482/35 nm; λemission = 536/40 nm) to
visualize WBCs.
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2.10. Signal Deconvolution and Data Analysis
The total SERS signal from a cell or solution is deconvolved (unmixed) with the direct
classic least squares (CLS) method to derive signal contribution from each nanotag using
Solo+MIA software (Eigenvector Research, Inc.). Specifically, the total SERS signal (Stotal) from
a mixture is considered as a linear addition of those from individual nanotags S1 to S4 on the
cell: Stotal = C1S1 + C2S2 + C3S3 + C4S4 + Δ, where C1 to C4 are the weight factor for the four
nanotags and Δ is the residual error to be minimized for optimal choices of the weight factors.
The weight factor for each nanotag is the relative SERS signal intensity to the SERS spectrum of
the pure nanotag solution. The SERS spectrum of the pure nanotag solution was collected with
25 pM (NP concentration) IO−Au SERS nanotags with a 100 μm Raman probe. The laser power
was 25 mW and the acquisition time was 1 s.
2.11. Simultaneous Detection of Multicolor SERS Nanotags in a Mixed Solution
To verify the accuracy of the CLS method for signal deconvolution, we prepared fourcolor SERS nanotags with mPEG-SH stabilization and made mixture solutions with varying
concentration of the individual nanotags. Specifically, QSY21, BHQ3, QXL680, or IR740
Raman reporters were added to IO−Au NPCs with a specific dye to particle molar ratios (15,000
for QSY21, 15,000 for QXL680, 45,000 for BHQ3, and 5000 for IR740) and mixed with
constant stirring for 15 min. Then, mPEG-SH (105 /NPC molar ratio) was added and the mixture
was incubated with constant stirring for 45 min at RT. The resulting SERS nanotags were
purified by centrifugation at 10,000 rpm for 10 min and redispersed in DPBS to obtain a 10 pM
solution. A series of mixture solutions were prepared by adding different amounts of four-color
nanotags with varied ratios. Raman signals of the different mixture solutions were collected and
signals were deconvolved to calculate the SERS weight factor for each nanotag in each solution.
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The experimental values were compared with theoretical values with linear regression to
calculate the accuracy of detection for each nanotag in each solution.
2.12. Comparison between ELISA and Multicolor SERS Method
The correlation of the ELISA results with those of SERS methods with cells suspended in
PBS and in blood was analyzed using a Pearson correlation test and their linear relationship was
assessed using curve fits. Additionally, the correlation between the SERS results in PBS and
blood was compared with each other in a similar fashion and the agreement between the two sets
was examined. The correlation coefficient r was calculated between the SERS mean weight
factor and the ELISA mean absorbance for each of the four markers in every cell line, yielding a
total of 12 data points for each of the three sets. The t-statistic was calculated from r using
Student’s t-distribution with degrees of freedom n − 2, as shown in eq 2.1. The p-value was
determined from the t-statistic based on a one-tailed distribution and a null hypothesis of r = 0.
𝑛−2

𝑡 = 𝑟√1−𝑟 2

(2.1)

The ELISA mean absorbance was plotted as a function of the mean weight factor of the
SERS method to examine the correlation between ELISA and SERS methods with standard
deviation (SD) for each sample. To assess the linear relationship between ELISA and SERS, the
SERS weight factor was fitted as a linear function f(x) of the ELISA absorbance (x) using an
ordinary least squares regression. The root-mean-square error (RMSE) of the fits was calculated
with respect to the ELISA absorbance (RMSEELISA) and the SERS weight factor (RMSESERS) to
estimate the lower and upper uncertainty bounds as shown in eq 2.2.
𝑓𝑏𝑜𝑢𝑛𝑑𝑠 = 𝑓(𝑥 ∓ 𝑅𝑀𝑆𝐸𝐸𝐿𝐼𝑆𝐴 ) ± 𝑅𝑀𝑆𝐸𝑆𝐸𝑅𝑆
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(2.2)

The same method is used to compare the results of the SERS method between PBS and blood.
The uncertainty bounds are defined by this RMSE, as presented in eq 2.3.
𝑓𝑏𝑜𝑢𝑛𝑑𝑠 = 𝑓(𝑥 ∓ 𝑅𝑀𝑆𝐸) ± 𝑅𝑀𝑆𝐸

(2.3)

3. Results and Discussion
3.1. Design of CTC Capture and Multiplexed Detection
Because of their scarcity in blood, identification of CTCs generally requires the
combination of enrichment and detection technologies. Materials that allow dual separation/
detection modalities are highly desirable in order to develop a simple, rapid, and efficient
detection method. We use magnetic-optical IO−Au NPCs to dually capture CTCs through
immunomagnetic separation and detect them with the SERS technique via the adsorbed Raman
reporter (Figure 2.1). Immunomagnetic separation is the most commonly used method to isolate
and enrich CTCs because it is rapid and highly specific. It avoids nontumor cells that are
morphologically similar to CTCs. Immunomagnetic separation under flow conditions is a highly
efficient way to capture NP-bound CTCs without capturing free magnetic NPs at appropriate
flow rates.86,108 This is because magnetic force is proportional to bound NP numbers.109 The free
NPs are more effectively removed by flow drag forces than the cells which contain a number of
NPs.
We perform the immunomagnetic separation in a microfluidic device. The microfluidic
device provides a venue for producing a highly integrated system that can process clinical
samples in closed architectures to minimize sample contamination and loss.110−112 It enables
user-friendly automation on a single device, reducing human intervention and operational errors.
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The microfluidic chip is very important for enriching low-frequency CTCs to reduce false
signals. It also allows on-chip staining for negative selection to reduce false positives. In
addition, it allows single-cell analysis so as to increase the detection accuracy. Cell isolation in
the channel can be simply achieved with permanent magnets under the chip.113−118 The capture
efficiency (percentage of captured cells over the total number of cells) and the sample throughput
can be precisely controlled through the design of the fluidic channel and the control of the flow
rate.

Figure 2.1 Design of CTC immunomagnetic capture and multiplexed detection with multicolor
IO−Au core−shell SERS nanotags. (A) Preparation of IO−Au SERS nanotags. By varying the
Raman reporter and the antibody, four-color IO−Au SERS nanotags were prepared to target four
different surface markers. (B) Methodology for CTC labeling, microfluidic-based magnetic
separation, and single-cell Raman detection using multicolor IO−Au SERS nanotags. Signals
from each SERS nanotag is obtained by deconvolution of a total SERS spectrum of single cells
with the classic least squares fitting method.
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To improve SERS detection sensitivity, we use anisotropic IO−Au NPCs. Anisotropic
NPs give orders of magnitude stronger SERS signals than the spherical counterparts because of
their stronger electronic field enhancement.44 We design four-color SERS nanotags to detect four
different surface cancer proteins including EpCAM and three breast cancer surface markers
HER2, CD44, and IGF1R. To quantify the expression of each targeted cancer marker, the total
SERS signal from individual cells was unmixed with CLS fitting to determine the level of each
nanotag on the cells. To increase the reliability of CTC detection, we performed counterstaining
with DAPI to confirm the presence of cell nucleus and with FITC-labeled CD45 antibodies to
identify WBC impurities. We performed all cell isolation/enrichment, negative staining, optical
imaging, SERS detection, and molecular profiling in a microfluidic device, which is simple and
easy to operate.
3.2. Properties of Multicolor IO−Au Core−Shell SERS Nanotags
IO−Au NPCs were synthesized via a seed-mediated growth method.43 Figure 2.2 (A−C)
shows typical TEM images of IO NPs, Au seed-coated IO NPs, and IO− Au NPCs. The IO−Au
NPCs, which were about100 nm in size, exhibited a localized surface plasmon resonance (LSPR)
peak at 620 nm, whereas the Au seed-coated IO NPs had an LSPR at 560 nm (Figure 2.2 D).
Systematic characterization in previous studies have shown that the IO−Au NPCs are core− shell
structures with ferromagnetic properties.43 Figure 2.2 E shows a photograph of the IO−Au NPCs
before and after separation with a 12-well tube magnet.
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Figure 2.2 Characterization of IO−Au NPCs and SERS nanotags. (A−C) TEM image of IO NPs
(A), Au seed-coated IO NPs (B), and IO−Au NPCs (C). (D) Absorption spectra of IO NPs, Au
seed-coated IO NPs, and IO−Au NPCs. (E) Photographic picture of IO−Au NPCs before (left)
and after (right) magnetic separation. (F) DLS characterization of the size distribution of IO−Au
NPCs and IO−Au SERS nanotags. (G) Confirmation of the presence of proteins on IO−Au NPCs
using HRP by the TMB assay. Left: IO−Au NPCs. Right: HRP-conjugated IO−Au NPCs. (H−K)
SERS spectrum of IO-Au SERS nanotags coated with QSY21 (H), BHQ3 (I), QXL680 (J), and
IR740 (K). (L) Examination of the stability of SERS nanotags. SERS signal intensities were
measured at 1497 cm−1 for QSY21, 1092 cm−1 for BHQ3, 1139 cm−1 for QXL680, and 501 cm−1
for IR740. They were normalized to the signal intensities at day 1 for each nanotag.
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The IO−Au SERS nanotags were prepared by nonspecific adsorption of Raman reporters
and covalent binding of targeting Ab through a PEG-HS linker with further stabilization by
mPEG-SH (Figure 2.1 A). To optimize the Ab surface density, we performed cellular binding
studies with the SERS NPs linked with different loading ratios of Ab to NP using HER2 Ab as
the model. The dark-field image shows that increasing the HER2 Ab loading ratio from 25 to
100 increased the amount of NPs on the HER2-positive SK-BR-3 cells (Figure S1). No
significant difference was observed when the HER2 loading ratio was increased from 100 to 200.
Thus, we used Ab/NP of 100 to prepare the SERS nanotags in all the studies. DLS measurements
showed that the Ab and PEG conjugation increased the size of IO−Au NPCs by 20 nm (Figure
2.2 F). The zeta potential decreased from +35 to −5 ± 10 mV. The color change in the TMB
assay showed the presence of proteins on the IO−Au NPCs (Figure 2.2 G). We further
determined the number of Abs per NP using the Micro BCA protein assay with IgG as the
protein model. The results showed that there were approximately 25 Abs bound to each IO−Au
NPC. (Figure S2 and Table S1).
For multiplexed detection, we made four-color SERS nanotags with four different
organic dyes, QSY21, BHQ3, QXL680, and IR740, to detect EpCAM, HER2, CD44, and
IGF1R, respectively. The loading ratio of these Raman reporters was adjusted to give similar
SERS signal intensity at their representative peak (Figure 2.2 H−K). The SERS nanotags were
relatively stable in PBS (Figure 2.2 L). At day 14 after preparation, all nanotags showed ≥85%
signal intensity of those at day 1 except IR740 nanotags. The SERS intensity of IR740 is 77% of
that at day 1. In our experiments, we used freshly prepared nanotags that have similar SERS
intensities at the representative SERS peak intensity (QSY21 at 1497 cm−1, BHQ3 at 1092 cm−1,
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QXK680 at 1139 cm−1, and IR740 at 501 cm−1). We further studied the stability of the nanotags
in whole blood. As the interaction of the nanotags with blood is less than 1 h (30 min for cellular
binding and 20 min for microfluidic magnetic separation), we focused our study within the first
few hours of mixing of the nanotags and blood from a healthy donor. The results from repeated
experiments (n = 3) showed that there were no significant differences among the four groups (t =
0, 0.5, 1.5, and 3.5 h) (Figure S3). Signal fluctuation is most likely due to the interference (such
as scattering of the Raman laser light) by the abundant blood cells during Raman measurement.
The SERS IO−Au NPs were further characterized by examining their cellular binding to three
model BC lines, SKBR-3, MDA-MB-231, and MCF-7. These cell lines have varied expressions
of EpCAM, HER2, CD44, and IGF1R,119−121 which we have confirmed with flow cytometry
(Figure S4).
We choose HER2, CD44, and IGF1R as additional markers for CTC recognition based
on their clinical significance in the BC model. HER2 is a member of the epidermal growth factor
receptor family having tyrosine kinase activity. It is overexpressed in 15−30% BC.122 CD44 is
associated with triple negative BC.123 IGF1R belongs to the large class of tyrosine kinase
receptors and is overexpressed in many cancers such as breast, colon, prostate, and nonsmall cell
lung.124 It plays an important role in breast cancer metastasis.125,126 In agreement with flow
cytometry data, the dark-field images show that SK-BR-3 has high levels (the presence of golden
color NPs) of EpCAM and HER2, MDA-MB-231 of CD44, and MCF-7 of EpCAM and CD44
(Figure 2.3). Expression of IGF1R is also significant on MCF-7 cells. These results suggest
specific binding of the four-color SERS nanotags to their targeted cancer proteins on different
cancer cell lines.
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Figure 2.3 Characterization of cellular binding of the four-color IO−Au SERS nanotags to
different breast cancer cell lines with dark-field imaging. The IO−Au NPCs were coated with
QSY21, QXL680, BHQ3, and IR740 and conjugated with anti-EpCAM, anti-HER2, anti-CD44,
and anti-IGF1R monoclonal antibodies, respectively. The bound NPCs are shown in golden color
in the dark-field images.
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3.3. Multicolor IO−Au SERS Nanotags for Quantitative Measurement of Surface Protein
Markers on Cancer Cells
SERS is very promising for multicolor detection because it gives narrow peaks. However,
a Raman reporter gives many peaks, which makes it difficult to identify one distinct peak for
each tag when three and more colors are needed simultaneously. To solve the limitation, an
alternative way is signal deconvolution using the reference spectrum from pure nanotag.127 The
deconvolution was done with CLS regression based on the fact that the total SERS signal from a
mixed solution is a linear combination of the SERS signals of individual nanotags (Figure S5).
The contribution of each tag is measured by the weight factor. To test the robustness of CLS for
signal deconvolution, we mixed the four-color SERS nanotags in various ratios, measured the
SERS spectrum of the mixture, and calculated the weight factor from each tag (Figure 2.4). The
results show that the experimentally measured fraction of a nanotag in the mixed solution
matches well with the theoretical values. For example, in the QSY21/BHQ3/ QXL680/IR740 =
2:1:1:1 sample, the intensity of the SERS spectrum from the QSY21 nanotag in the mixture
solution is 2/5 of that of the pure QSY21 nanotag because of the dilution by other three nanotags.
Thus, the theoretical CQSY21 is 0.4. The CQSY21 calculated by CLS fitting is 0.400094. The
theoretical values of CBHQ3, CQXL680, and CIR740 are 0.2. The calculated CBHQ3, CQXL680, and CIR740
are 0.18529, 0.21252, and 0.20075, respectively. The accuracy for the detection of QSY21,
BHQ3, QXL680, and IR720 nanotags is 99.98, 92.65, 93.74, and 99.62%, respectively (Table
S2). The mean accuracy of detecting all nanotags in all the samples is 95.53%.
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Figure 2.4 Examination of the accuracy of multicolor SERS nanotags with CLS fitting for
multiplexed detection. (A) Plot of experimentally measured SERS weight factors vs theoretical
weight factors for each nanotag in each mixed solution. (B) Linear correlation of the measured
and theoretical values.

To examine the ability of the multicolor IO−Au SERS nanotags for multiplexed
detection, we incubated each of SK-BR3, MDA-MB-231, or MCF-7 cells in PBS with a cocktail
of four-color nanotags for 45 min and separated the labeled cells from free nanotags by lowspeed centrifugation. The cells were placed on a quartz coverslip and SERS signals from
individual cells were collected with a Raman microscope. Fifty cells were measured and CLS
regression was used to extract the signals from each nanotag for each cell. The weight factor for
each nanotag on each cell (n = 50) is shown in Figure 2.5 A. The results show that the expression
is certainly heterogenous at the single-cell level. To better compare the expression levels of
different markers, we repeated three times and the mean with SD is plotted in Figure 2.5 B. The
results show that EpCAM and HER2 are highly expressed on SK-BR-3 cells, CD44 on MDAMB-231 cells, and EpCAM and CD44 on MCF-7 cells, which are consistent with flow cytometry
results (Figure S2) and dark-field imaging (Figure 2.3). It is important to mention that the SERS
weight factor is the relative intensity of the SERS spectrum of a nanotag on a cell to a reference
SERS spectrum of the pure nanotag we defined.
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Figure 2.5 Detection of surface protein markers on cancer cells in PBS with four-color IO–Au
SERS NPs. (A) SERS weight factor of each marker from 50 individual cells. (B) Mean SERS
weight factor from triplicate measurement of the protein markers for each cell line.
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In our studies, we used 25 pM IO−Au SERS nanotag solution to collect the reference spectra
(shown in Figure 2.2). The signals were taken using a 100 μm Raman probe with a laser power
of 25 mW and an acquisition time of 1 s. Based on the sample volume under the Raman probe
and the concentration of the nanotag solution, we estimated that the signals of the reference
SERS spectrum were produced by 6 × 105 nanotags. To generate the same strength of SERS
signals under the cell measurement conditions (laser power: 100 mW; acquisition time: 10 s), it
will require approximately 1.5 × 104 nanotags. Based on this information, together with the value
of the SERS weight factor, we can estimate the number of nanotags bound to each surface
protein. For example, in the SKBR3 cell line, the weight factor for EpCAM, HER2, CD44, and
IGF1R was 0.56, 0.85, 0.09, and 0.01, respectively. Therefore, the estimated number of nanotags
bound to EpCAM, HER2, CD44, and IGF1R is 8400, 12750, 1350, and 150, respectively.
3.4. Immunomagnetic Cell Capture in the Micro-fluidic Chip
To detect CTCs in blood, we fabricated a microfluidic device to isolate the tumor cells
with an external magnet from the blood components and free NPs and immobilize them on the
chip for optical detection. The device was designed in such a way that it meets the following
criteria: (1) transparent for optical imaging and detection; (2) with no or minimal fluorescence
and Raman background signals; (3) flat channel surface; (4) with laminar flow in the channel; (5)
with high throughput for processing large volumes of sample; (6) adaptable with the Raman
detection system, and (7) cost effective.
Figure 2.6 A−C shows the schematics of the chip that shows the dimension of the chip
and magnetic separation with a permanent magnet underneath. Figure 2.6 D is a photograph of
the fabricated chip with the holder and collecting tubes. The chip was made of two transparent
quartz slides that were fused together to form an isolation and detection chamber. Unlike
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polymer-based materials, quartz has no Raman background and is nonfluorescent. The top slide
contained the inlet and outlet ports, whereas the bottom slide had the microfluidic chamber (20 ×
5 × 0.1 mm) and connection channels with a depth of 100 μm. Six ports were designed to have
different functions, with port (A) for supplying blood samples, (B) PBS to wash the cells after
each step, (C) paraformaldehyde solution to fix the cells, (D) FITC-conjugated CD45 antibodies
to label WBCs, (E) DAPI to counterstain the cell nucleus, and (F) to act as a waste outlet. The
chamber held ∼10 μL solution. The dead volume in each side channel was less than 1 μL. The
channel bends were angled at 60° or less along the flow direction to reduce sheer stress on the
cells flowing with the fluids. These angular junctions, a bioinspired approach mimicking blood
vessel branching, minimize vortex formation and allow smooth laminar flow of fluids inside the
channels. The chip was placed on top of a NdFeB magnet (D = 20 mm and L = 25 mm) with the
channel centered on the magnet. The surface field of the magnet was 5000 Gauss. Because of the
short distance between the surface of the magnet and the channel (1 mm), the field at the channel
was estimated to be the same as that on the surface of the magnet.
To determine a flow rate to preferentially capture cancer cells over free NPs, we
examined the effect of capture efficiencies of IO−Au NPCs and SK-BR-3 cells prelabeled with a
cocktail of anti-EpCAM- and anti-HER2-conjugated IO−Au nanotags (Figure 2.6 E). When the
flow rate increased from 10 to 200 μL/min, the capture efficiencies of the cells decreased from
90 to 82% and the IO-Au NPCs decreased from 38 to 7%. To consider both the speed and the
cell capture efficiency, we choose 50 μL/min as the working flow rate to capture cancer cells in
blood for detection. At this flow rate, about 20% free NPs were captured. To minimize the effect
of the captured free NPs, SERS signals from the individual cells were subtracted with the
background spectrum that was taken from an area in the chip without cancer cells.
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Figure 2.6 Design and characterization of the microfluidic device for on-chip magnetic isolation
and optical detection of CTCs. (A) 3D view, (B) layout, and (C) cross-sectional view (not to
scale) of the microchannel with a magnet underneath. (D) Photograph of the fabricated
microfluidic device. (E) Capture efficiencies of SK-BR-3 cells labeled with a cocktail of antiEpCAM and anti-HER2 IO−Au NPCs (red curve) and free IO−Au NPCs (black curve).

3.5. Multiplexed Surface Protein Marker Detection of Spiked Cancer Cells in Human Whole
Blood
To mimic CTCs, we spiked breast cancer cells into 1 mL of human blood from healthy
donors. Three cell lines, SK-BR-3, MDA-MB-231, and MCF-7, were used to test the validity of
our technique as these cells have varied expressions of EpCAM, HER2, CD44, and IGF1R.
Following the procedure described above in the Experimental Section, we obtained the
fluorescence images and the Raman spectrum of captured cells in the microfluidic device. We
determined that a cell was a cancer cell when it satisfied the following criteria: (1) it met
morphologic features (nearly round or oval morphology); (2) it had a visible nucleus (DAPI
positive); (3) it was CD 45 negative, and (4) it was EpCAM, HER2, CD44, or IGF1R positive. A
cell was identified EpCAM-, HER2-, CD44-, or IGF1R-positive when it was SERS-positive. A
cell was defined as SERS-positive based on the Rose criterion, in which the intensity of the
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Raman peak of the reporter from a whole cell was at least 5 times higher than the SD of the
background noise collected from a neighborhood area without cells. The spectra from both signal
and noise were automatically baseline-corrected in advance using a multisegment polynomial
fitting to subtract the weak fluorescence and SERS background (broad continuum emission).
This baseline correction was applied for all the Raman spectra we obtained in this study.
Figure 2.7 A−C shows an example of the optical images of a captured cancer cell in
bright- and fluorescence-imaging modes. Bright-field imaging showed the round morphology of
a cancer cell. The cell was DAPI-positive and CD45- negative, which further confirmed the
cancer cell features. In contrast, a WBC showed positive staining with FITC-CD45 antibodies
and was excluded in the following SERS analysis (Figure 2.7 D)
Figure 2.7 E shows the distribution of the weight factors for each nanotag across 50
cancer cells from each cell line, with the mean ± SD being plotted in Figure 2.7 F. The results
from cells in blood was similar to those in PBS, as shown in Figure 2.5. Again, EpCAM and
HER2 were highly expressed on SK-BR-3 cells, CD44 on MDA-MB-231 cells, and EpCAM and
CD44 on MCF-7 cells. To validate the multicolor SERS method for analysis of tumor cells in
blood, we measured protein expressions with indirect ELISA using the same primary antibodies
as those in the SERS methods. Figure 2.8 A−C shows the level of EpCAM, HER2, CD44, and
IGF1R expression on the three cancer cell lines. Similar to the SERS method (Figures 2.5 and
2.7), EpCAM and HER2 were highly expressed on SK-BR-3 cells, CD44 on MDA-MB-231, and
EpCAM and CD44 on MCF-7 cells.
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Figure 2.7 Detection of surface protein markers on spiked cancer cells in human blood with
four-color IO–Au SERS nanotags. (A) Bright-field image of a cancer cell. (B) Fluorescence
image of the cell in (A) with a DAPI filter showing the cell nucleus. (C) Fluorescence image of
the cell in (A) with a FITC filter showing the cell is CD45-negative. (D) Fluorescence image of a
WBC cell with a FITC filter showing the cell is CD45-positive. (E) Plot of SERS weight factor
across individual cancer cells (n = 50). (F) Mean SERS weight factor from triplicate
measurements of the protein markers for each cell line.
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To quantitatively examine the correlation between ELISA and SERS methods, the ELISA
mean absorbance was plotted as a function of the mean weight factor of the SERS method using
cancer cells suspended in PBS or blood (Figure 2.8 D,E). The results showed that the SERS
method was strongly correlated with ELISA, with high correlation coefficients (r ≥ 0.97) and
low p-values (p < 10−6). The coefficients of determination R2 for the linear fits between ELISA
and SERS (black lines) were relatively high, with R2 > 0.94. Nearly all the points fell within the
uncertainty bounds of the fit (red lines). The RMSESERS and RMSEELISA in Figure 2.8 D were
0.0792 and 0.1117, respectively. The RMSESERS and RMSEELISA in Figure 2.8 E were 0.0956
and 0.1212, respectively. This suggests a strong linear relationship between the results of ELISA
and SERS with virtually no outliers. The one exception was CD44 expression in MDA-MB-231,
where the mean weight factor was slightly higher than the upper bounds. However, the error bars
still overlapped with the upper bound in both Figure 2.8 D,E.
To assess the effects of the cell matrix (PBS and blood), the mean weight factor of SERS
in blood was plotted against the mean weight factor of SERS in PBS (Figure 2.8 F). The black
line was the identity line on which the SERS weight factors in PBS and in blood were equivalent
to each other. The result showed that the 10 lowest expressing points were almost exactly on the
identity line, indicating that the SERS measurement of cells suspended in blood was nearly
identical to those cells suspended in PBS for lower expression levels. As expected, the
correlation coefficient was very high, with r = 0.993. The corresponding p-value was extremely
low, with p = 4.7 × 10−11. To quantitatively examine the agreement between the two sets, the
RMSE was calculated between their weight factors and determined to be RMSE = 0.06203, a
value that was low enough to distinguish between negative and positive marker expression for
both sets. The HER2 expression in SK-BR-3 fell above the upper bound but still had error bars
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that overlap (red lines). The highest expressed point, corresponding to CD44 expression in
MDA-MB-231, fell off the identity line but still remained within the uncertainty bounds.

Figure 2.8 Correlation of multicolor SERS method with ELISA. (A–C) Expression level of
surface protein markers of different cell lines with ELISA. (D,E) Plots of SERS mean weight
factor as a function of the ELISA mean absorbance for SERS with cells in PBS (D) and with
cells in blood (E). (F) Plot of the SERS mean weight factor with cells in blood as a function of
the SERS mean weight factor with cells in PBS. The black line is the linear fit and the red lines
represent the uncertainty bounds.

4. Conclusions
Using spiked cancer cells in blood to mimic CTCs, we have shown that CTCs can serve a
dual purpose of isolation from human whole blood and detection with IO−Au core−shell SERS
nanotags in a microfluidic device. By varying the Raman reporters and targeting ligands, fourcolor SERS nanotags targeting four different cancer markers were prepared. With the assistance
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of CLS deconvolution, EpCAM, HER2, CD44, and IGF1R on single breast cancer cells were
simultaneously detected. Using ELISA as the reference method, we showed that our method can
accurately detect multiple cancer markers on different cell lines, suggesting that our method has
the potential to simultaneously detect CTCs of multiple subpopulations in clinical samples. In
our method, all cell isolation/enrichment, negative staining, optical imaging, SERS detection,
and molecular profiling were performed on a microfluidic device. The microchip device
increases the degree of operational automation, facilitates single-cell analysis, and reduces false
negative signals by concentrating low-frequency tumor cells. We bridge the isolation and
detection techniques with “all-in-one” IO−Au SERS nanotags, making the sample preparation
simple and easy to operate. CTC identification is based on a combination of several parameters
at the single-cell level. We used SERS for molecular cancer cell detection. We also used
supplementary fluorescence imaging to recognize blood cell impurities and bright-field imaging
to confirm cancer cells with morphological criteria. The combinatory criteria reduce false
positives and ensure detection accuracy.
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Chapter 3. OPTIMIZING CELLULAR BINDING OF
LIGAND-CONJUGATED GOLD NANOPARTICLES
1. Introduction
Due to the intriguing surface plasmon resonance (SPR)-enhanced optical properties, gold
nanoparticles (AuNPs) have attracted intense research interests for decades.128-130 AuNPs absorb
and scatter light orders of magnitude stronger than non-metallic NPs and individual organic
dyes.131 Under dark field light scattering imaging, AuNPs appears as bright fluorescence
analogs.132 Different from fluorescence dyes, AuNPs do not photo-bleach. AuNPs are highly
efficient photothermal agents. The absorbed light can be converted to heat within picosecond.133
Thus, AuNPs have been widely used for a variety of biomedical applications, including cancer
imaging, spectroscopic detection, photothermal therapy, radiotherapy, and drug delivery.2,134-137
To use AuNPs effectively as diagnostics and therapeutic agents, AuNPs need specifically
and sensitively bind to target of interests on cancer cells. A major important parameter is surface
chemistry of the NPs. Targeting specific ligand, such as antibodies, peptide, oligonucleotide, and
aptamer are generally chemically immobilized on to AuNPs. The most common method is
through robust thiol chemistry. The ligand is either modified with a thiol linker to bind to AuNPs
or through a heterofunctional linker that binds to AuNPs on one end and to the ligand on the
other end. In addition, a protective agent, often polyethene glycol (PEG), is used to increase the
stability of the conjugates. Literature has reported many different approaches for the formulation
of the light-conjugated and PEG stabilized AuNPs. However, a systemic evaluation on the effect
of ligand density and role of PEG on targeted cellular labeling are lacking.
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Detection of target of interests on cancer cells has two ways, direct and indirect targeting.
For the direct targeting. Ligand-conjugated AuNPs directly bind to cell surface markers or to
antibodies that are bound to cells in advance. In the indirect method, primary antibodies bind to
cells first, followed by secondary antibodies. The ligand-conjugated AuNPs recognize secondary
antibodies. Compared to direct method, the indirect method requires the use of secondary
antibody. But, it is flexible for detection of multiple surface markers as the primary antibody
does not need chemical modification. For both studies, literature have reported the use of
different matrix for the primary and second antibodies. Most studies use phosphate buffered
solution (PBS) with 1-5% bovine serum albumin (BSA) that blocks nonspecific cellular binding
of the antibodies. Other studies use low concentration of tween-20 to block nonspecific
bindings. But, it is not clear what is the best binding conditions. A side-by-side comparison is
needed to optimize cellular targeting and labeling.
In this study, we performed a systemic study on the effects of surface chemistry of
ligand-conjugated AuNPs and the binding conditions to detect cancer cell surface protein
markers. We use streptavidin (SA) as the protein ligand model. MDA-MB-231 breast cancer
cells was used as the cancer cell model, with the high expression CD44 protein marker as the
surface target. We examined both direct and indirect labeling method in which biotin was
conjugated to primary antibody and secondary antibody, respectively. Using dark field imaging
to examine the cellular binding, we have found optimal SA-AuNP formulation and the cellular
binding conditions. The results will benefit many fundamental and applied research using ligandconjugated AuNPs and other types of NPs.
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2. Materials and Methods
2.1 Materials
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless speciﬁed.
CD44 antibodies and biotin-CD44 antibodies were purchased from Biolegend (San Diego, CA).
MDA-MB-231 cells were purchased from ATCC (Manassas, VA). Colloidal gold (50 nm in
diameter) was purchased from Ted Pella (Redding, CA). Dulbecco's Modified Eagle Medium
(DMEM) with high glucose (4.5 g/L), 0.25% trypsin, and 100 U/mL HyClone PenicillinStreptomycin (P/S) were purchased from VWR (Atlanta, GA). Biotin-secondary antibodies, fetal
bovine serum (FBS) and non-essential amino acids (NEAA) were purchased from Fisher
Scientific (Waltham, MA). Streptavidin-thiol (SA-SH) was purchased from Nanocs (New York,
NY).
2.2 Synthesis and characterization of SA-conjugated AuNPs
To 200 µL of as-purchased 50-nm AuNP solution (75 pM) in a non-stick plastic vial, 10
µL tween-20 in 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH7 was
added. Then, SA-SH was added with different loading SA-to-AuNP molar ratios from 0 to 10,
000. The solution was mixed via gentle vortexing for 1.5 h at RT. Then, 4.5 µL of 0.1 mM
methoxyl-polyethenly glycol thiol (mPEG-SH) with molecular weight of 2000 or 5000 was
added and mixed for another 1.5 h at RT. At the end, the solution was centrifuged (10,000 rpm,
10 min) and the conjugates were resuspended in 300 µL of phosphate buffered solution (PBS)
containing 0.05% (w/v) tween-20. This process was repeated for two more times. The final
conjugates were resuspended in 200 µL PBST0.05% with 0.05% (w/v) sodium azide and stored
at 4oC before use.
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2.3 Cell Culture
MDA-MB-231breast cancer cells were cultured in DMEM with 10% fetal bovine serum,
1% NEAA, 100 U/mL penicillin, and 0.1 mg/mL streptomycin at 37°C with 5% CO2. To label
surface protein markers, cells were cultured in an 8-well chamber slide of 5 x 104 cells/well for
72 h.
2.4 Indirect detection of cell surface protein markers with SA-conjugated AuNPs
MDA-MB-231 cells cultured in an 8-well chamber slide were washed with PBST0.05%
and fixed with 1% formaldehyde at room temperature (RT) for 15 min. The cells were blocked
with 1% BSA for 30 min at 37oC, followed by two times washing with PBS. Then, the cells were
incubated with 150 µL of 5 µg/mL CD44 antibodies (CD44-Ab1) diluted in PBS, PBS with 1%
BSA, or in PBST0.05% for 1 h at 37oC. After washing three times with PBST0.05%, the cells
were incubated with 150 µL of 5 µg/mL biotin-secondary antibodies (biotin-Ab2) diluted (1:60)
in PBS, PBS with 1% BSA or PBST0.05% for 1 h at 37oC. After washing three times with
PBST0.05%, the cells were incubated with 150 µL of 20 pM of SA-AuNP conjugates with
different SA-to-AuNP loading ratios from 0 to 10,000 in PBS with 0.1% BSA, PBS with 1%
BSA or PBST0.05% for 1 h at 37oC. The cells were washed three times with PBST0.05%
followed by two times washing within PBS before imaging. The experiments without using
CD44-Ab1 were performed as the negative controls.
2.5 Direct Detection of Cell Surface Protein Markers with SA-conjugated AuNPs
MDA-MB-231 cells cultured in an 8-well chamber slide were washed with PBST0.05%
and fixed with 1% formaldehyde at room temperature (RT) for 15 min. The cells were blocked
with 1% BSA for 30 min at 37oC, followed by 2 times washing with PBS. Then, the cells were
48

incubated with 150 µL of 5 µg/mL biotin-CD44 Ab1 diluted in PBS, PBS with 1% BSA, or in
PBST0.01% for 1 h at 37oC. After washing three times with PBST0.05%, the cells were
incubated with 150µL of 20 pM of 5K SA-AuNP conjugates diluted in PBST0.05% for 1 h at
37oC. The cells were washed three times with PBST0.05% followed by two times washing
within PBS before imaging. The experiments without using biotin-CD44 Ab1 were performed as
the negative controls.
2.6 Characterization of SA-conjugated AuNPs and Their Cellular Binding
Size and zeta potential of the conjugates were measured by dynamic light scattering
(DLS) using a Zetasizer Nano ZS (Malvern Instruments). Absorption spectra were measured
with an UV-Vis absorption spectrometer (Shimadzu Scientific Instruments). Cellular binding of
the SA-conjugated AuNPs were characterized by dark field imaging using an Olympus IX71
inverted microscope with a 40x objective.
3. Results and Discussion
3.1 Design of the Studies
Cellular targeting and imaging are usually done in two different ways, direct and indirect
detections (Figure 3.1). In direct detection, the labeling agent is directing the primary antibodies.
In indirect method, the labeling agent is detecting secondary antibody that recognizes the
primary antibodies. Compared to the direct method, the indirect method has one more step, but
there is no need of chemical modification of the primary antibody. This is advantageous in
efficiency for detecting multiple surface markers.
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Figure 3.1. Schematic of the preparation of SA/AuNPs with different formulations for cancer
marker detection. SA-thiol is bound to AuNPs via Au-S bond. A series of formulations are
formed by varying the surface density of SA and subsequent binding with mPEG-SH with
different molecular weight. Cellular binding were tested in two different approaches, direct
binding with biotin-conjugated primary antibody and indirect binding with biotin-conjugated
secondary antibody.

To investigate the two targeting methods, we make use of the high affinity and high
specificity streptavidin-biotin binding. We functionalize AuNPs with streptavidin. In the direct
method, we use commercially available biotin-conjugated antibodies. The biotin-conjugated
antibodies bind to targeted surface protein marker on cells and then recognized by SAconjugated AuNPs. In the indirect method, targeted surface markers are recognized by primary
antibody. Then, the primary antibody was recognized by biotin-conjugated secondary antibody.
Lastly, the biotin-conjugated secondary antibody is recognized by SA-conjugated AuNPs. To
detect AuNPs, we use dark field imaging to. Due to their intense localized surface plasma
resonance (LSPR), AuNPs exhibit strong light-scattering properties.128,138 Thus, AuNPs can be
easily detected under dark field, which makes them attractive fluorescence analogs for
biomedical imaging via dark field light scattering imaging with a regular optical
microscope.130,139
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Surface chemistry determines the binding affinity and specificity of AuNPs. To
investigate the effect of surface chemistry, we made SA-conjugated AuNPs with different
surface density of SA. We also examine the role of stabilizing PEG by making the SAconjugated AuNPs without PEG and without PEG. The effect of the size of PEG is examined by
varying the molecular weight and thus the chain length of PEG. We use MDA-MB-231 breast
cancer cells as the model to examine cellular binding. CD44, a high expression cancer marker on
MDA-MB-231 cells, was used as the surface protein target.
3.2 Synthesis of SA-conjugated AuNPs
SA-conjugated AuNPs were prepared by reacting SA-SH with bare AuNPs with different
SA to AuNP loading molar ratios via constant mixing for 1.5 h at RT in a centrifuge 1.5 mL vial.
To minimize the adsorption of protein-bound AuNPs to the plastic vial, the reaction was
performed in 1% v/v tween-20. To prevent the aggregation of AuNPs, the reaction was
performed in 20mM pH7.0 HEPES buffer. Then, the SA-conjugated AuNPs was followed by
PEGylation or directly purified by centrifugation. We use excessive PEG-SH2K or PEG-SH5K
(30,000:1 = PEG: AuNP) to saturate the surface of the SA-conjugated AuNPs. The final
conjugates were purified by centrifugation and washing with PBST0.05%. Again, tween-20 was
used during washing steps to minimize the adsorption of the conjugates to the plastic vials. The
conjugates were stored in PBST0.05% with 0.05% (w/v) sodium azide. Alternatively, the
conjugates can be stored in low-protein binding vial (Fisher Scientific) in PBS without tween. It
is worthy to note that the protein-bound AuNPs were heavily adsorbed to plastic vials without
tween-20 during the reaction or storage. So, tween-20 is critically important in preparation,
handling, and storage of protein-functionalized NPs unless low-protein binding vials were used.
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3.3 Characterization of SA-conjugated AuNPs
The SA-conjugated AuNPs were characterized by DLS and absorption spectroscopy for
hydrodynamic size and LSPR, respectively (Table 3.1, Figure 3.2). It is very interesting to note
that the hydrodynamic size varies before and after centrifugation-based purification depending
on the surface chemistry. Figure 3.2 A&B show the hydrodynamic sizes of SA/mPEGSH2K/AuNPs with different SA to AuNP loading ratios before and after centrifugation. The bare
AuNPs is 48.5 nm. Before centrifugation The AuNPs modified with mPEG-SH2K only, the
conjugates were 50.5 nm before centrifugation and 63.5 nm after centrifugation. This revealed
that the centrifugal force changed the conformation of PEG, leading to increased thickness of the
polymer layer on the surface of AuNPs. After centrifugation, the thickness of mPEG-SH was
about 6 nm.
Table 3.1: Characterization of the particle size of purified SA-conjugated AuNPs
Bare AuNPs
mPEG2k/AuNPs
mPEG5k/AuNPs
0.25k SA/mPEG2k/AuNPs
0.6k SA/mPEG2k/AuNPs
1k SA/mPEG2k/AuNPs
2k SA/mPEG2k/AuNPs
5k SA/AuNPs
5k SA/mPEG2k/AuNPs
5k SA/mPEG5k/AuNPs
8k SA/mPEG2k/AuNPs
10k SA/mPEG2k/AuNPs

Hydrodynamic size (nm)
48.5
63.5
74.6
78.7
95.0
108.4
84.5
60.3
67.4
64.9
60.1
59.0

The size of AuNPs at 1.5 h after SA addition increased with increasing SA-to-AuNP
loading ratio from 55 nm for 0.25k SA/mPEG/AuNPs to 65.2 nm for 10k SA/mPEG/AuNPs.
After mPEG-SH saturation and centrifugation, the size of the conjugates changed depending on
the SA to AuNP loading ration (Figure 3.2 C&D).
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D

E

Figure 3.2. Characterization of SA-AuNPs with different SA to AuNP loading ratios. (A)&(B)
Hydrodynamic size before addition of mPEG-SH 2K and purification. (C)&(D) Hydrodynamic
size after mPEG-SH addition and purification. (E) Absorption spectra.
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When the SA to AuNP ratio increased from 0.25k to 1k, the size increased from 78.7 nm to 108.
4nm. However, continuous increasing of the SA to AuNP ratio from 1k to 8k decreased the size
of the SA/mPEG/AuNPs from 108.4 nm to 60.1 nm. Further increasing of the SA-to-AuNP ratio
to 10k did not significantly decrease the size of the particles. Based on the size of bare AuNPs
(48.5 nm) and SA (~ 5 nm), we estimate that SA/AuNPs should be ~ 59 nm. The
mPEG2k/AuNPs was 63.5 nm. So, the size of SA/mPEG2K/AuNPs should be between 58 to 64
nm. The conjugates with 8k and 10k SA to AuNP loading ration fell within this range and thus
they were monodisperse NPs. The conjugates with significantly larger size, including 0.25k,
0.6k, 1k, and 2k/mPEG/AuNPs were thus aggregated. Figure 3.2 E shows the absorption spectra
of the AuNPs at 1.5 h after SA addition. The results show that there were no significant change
on the LSPR wavelength after SA addition. This also suggests the SA binding was performed
without aggregation.
3.4 Effect of SA-to-AuNP Loading Ratio to Cellular Binding
Figure 3.3 shows the dark field images of CD44 targeting MDA-MB-231 cells after
labeled with SA/mPEG2k/AuNPs by the indirect method. In this study, CD44 primary antibody
was diluted in PBS and biotin-secondary antibody was diluted in 1% BSA. SA/mPEG2K/AuNPs
with varied SA-to-AuNP loading ratios were diluted in PBST0.05%. The negative control was
the experiment without CD44 primary antibody. The results show that 5k SA/mPEG2K/AuNPs
and 10k SA/mPEG2K/AuNPs bound to the cells very well, which was indicated by high density
green scattering AuNPs. The 0.25k SA/mPEG2K/AuNPs barely bound to the cells. There were
some aggregated NPs (shown as red aggregates) for the 0.6k SA/mPEG2K/AuNPs. More
particles were found on the cells from 2k SA/mPEG2K/AuNPs compared to 0.25k and 0.6k
SA/mPEG2K/AuNPs. The negative controls for all formulations did not bind to the cells. These
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studies showed that cellular binding of SA/mPEG2K/AuNPs depends on ligand density, with
higher ligand leading to better cellular binding. To achieve effective cellular labeling without
particle aggregation, a SA-to-AuNP loading ratio of 5000 or higher is needed to make specificity
and sensitive monodisperse SA/mPEG2k/AuNPs.
(A) 0K

(B) 0.25K

(C) 0.6K

(D) 2K

(E) 5K

(F) 10K

CD44targetd

Negative
control

CD44targetd

Negative
control

Figure 3.3. Examining the effect of SA loading ratio on the cellular binding of AuNPs. CD44
primary antibody was diluted in PBS and biotin-secondary antibody was diluted in 1% BSA.
SA/mPEG2K/AuNPs with varied SA to AuNP loading ratios were diluted in PBST0.05%. CD44
on MDA-MBA-231 cells was used as the surface marker target. Negative control was the
treatment without CD44 Ab1.
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3.5 Effect of Binding Matrix of Primary and Secondary Antibody to Cellular Binding
Figure 3.4 shows dark field images of CD44-targeting MDA-MB-231 cells when using
primary and secondary antibody in three different matrix, PBS, PBS with1% BSA and PBS with
0.05% tween-20. The results show that when CD44 primary antibody (CD44-Ab1) suspended in
PBST0.05% showed best binding, followed by PBS with 1% BSA, and PBS only. For the
secondary antibody, the biotin-secondary antibody (biotin-Ab2) showed best binding among the
three matrices, although all three showed good bindings. The negative controls for all cases did
not bind to the cells, indicating excellent specificity of the primary and secondary antibodies.
These studies suggest that suspension of combination of primary antibody in PBST0.05% and
secondary antibody in PBS with 1% BSA gave the best cellular binding than other binding
matrices.
3.6 Effect of Binding Matrix of SA-conjugated AuNPs to Cellular Binding.
Figure 3.5 shows dark field images of CD44-targeting MDA-MB-231 cells when SAconjugated AuNPs were suspended in PBS with 0.1% BSA, 1% BSA, and tween-2 0.05%. In
this study, 5K SA/mPEG2K/AuNPs were used as the model conjugate. The results showed that
the 5K SA/mPEG2K/AuNPs suspended in PBST0.05% showed highly specific and efficient
binding to the cancer cells. In contrast, heavy nonspecific binding of the conjugates in PBS with
0.1% or 1% BSA to the chamber slide were found. In addition, the NPs aggregated with the
presence of BSA. This is most likely due to the biotin impurity in the commercial BSA. It is
known that the purity of BSA varies based on the commercial resources. Most BSA contains
biotin impurity. Thus, for the use of SA-conjugated AuNPs, biotin-free BSA is needed to avoid
NP aggregation.
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(A) CD44 Ab1 in PBS

(B) CD44 Ab1 in 1% BSA

(C) CD44 Ab1 in PBST0.05%

(D) Biotin-Ab2 in PBS

(E) Biotin-Ab2 in 1% BSA

(F) Biotin-Ab2 in PBST0.05%

CD44targetd

Negative
control

CD44targetd

Negative
control

Figure 3.4. Examining the effect of different matrix on cellular binding of the primary and
secondary antibodies with SA-conjugated AuNPs. (A-C) CD44 Ab1 was diluted in PBS (A), 1%
BSA (B), and PBST0.05% (C). Biotin-Ab2 was diluted in PBST0.05%. (D-F) Biotin-Ab2 was
diluted in PBS (D), 1% BSA (E), and PBST0.05% (F). CD44 Ab1 was diluted in PBST0.05%. In
all cases, SA/mPEG-SH2k/AuNPs (SA: AuNP = 10K:1) were diluted in PBST0.05%. CD44 on
MDA-MBA-231 cells was used as the surface marker target. Negative control was the treatment
without CD44 Ab1.
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(A) 0.1% BSA

(B) 1% BSA

(C) PBST0.05%

CD44targetd

Negative
control

Figure 3.5. Examining the effect of different matrix on the cellular binding of SA-conjugated
AuNPs. SA/mPEG-SH2k/AuNPs (SA:AuNP = 5K:1) were diluted in 0.1% BSA (A), 1% BSA
(B) and PBST0.05% (C). CD44 Ab1 was diluted in PBS and biotin-Ab2 was diluted in 1%
BSA. CD44 on MDA-MBA-231 cells was used as the surface marker target. Negative control
was the treatment without CD44 Ab1.

3.7 Effect of Binding Matrix of Biotin-conjugated Primary Antibody to Cellular Binding in the
Direct Method
The studies discussed above all used the indirect detection method. For the direct
method, only biotin-CD44 Ab1 is used. Figure 3.6 shows the effect of matrix for suspension of
the biotin-CD44 Ab1 to cellular binding. Both PBS with 1% BSA and PBST0.05% gave highly
efficient binding. The PBS showed lower amount of AuNPs than PBS with 1% BSA or 0.05%
tween-20. In the indirect method, PBST0.05% showed best binding than other matrix (Figure
3.4). Thus, primary antibody diluted in PBST0.05% is recommended for both direct and indirect
method for cellular labeling.
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Biotin-CD44 Ab1
in PBS

Biotin-CD44 Ab1
In 1% BSA

Biotin-CD44 Ab1
in PBST0.01%

CD44targetd

Negative
control

Figure 3.6. Examining the effect of different matrix on the biotin-conjugated primary antibodies
with SA-conjugated AuNPs. CD44-biotin was diluted in PBS, 1% BSA, and PBST0.01%.
SA/mPEG-SH2k/AuNPs (SA: AuNP = 5K:1) were diluted in PBST0.005%.

3.8 Effect of PEG Stabilizer on the Cellular Binding of SA-conjugated AuNPs
To examine the effect of PEG on the cellular binding of the SA-conjugated AuNPs, we
made the conjugates with SA only (SA/AuNPs), with both SA and mPEG-SH 2k
(SA/mPEG2k/AuNPs), and with both SA and mPEG-SH5k (SA/mPEG5k/AuNPs), in which SAto-AuNP ratio was 5000. Figure 3.7 A-C shows the hydrodynamic size before and after
centrifugation. Again, centrifugation led to an increase of the size of the conjugate when PEG
was used. For the SA/AuNPs, there was no effect on the particle size by centrifugation. The size
of the SA/AuNPs was about 59 nm, suggesting the thickness of SA on the particle surface was
approximately 5 nm. For the purified particles, the size of mPEG5k/AuNPs was 74.6 nm, which
is nearly 10 nm larger than the mPEG2k/AuNPs and 25 nm larger than the bare AuNPs.
Compared to SA/AuNPs, the sizes of SA/mPEG2k/AuNPs and SA/mPEG5k/AuNPs increased
by 7 nm and 5 nm, respectively. It is interesting to note that there is no significance difference in
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the particle size for the SA/mPEG2k/AuNPs and SA/mPEG5k/AuNPs. Thus, the PEG chain
length did not affect significantly the overall size of the protein conjugates, although it changes
dramatically the size of AuNPs with PEG modification only.
A

D

B

SA/AuNPs

SA/mPEG2K/AuNPs

C

SA/mPEG5K/AuNPs

CD44targetd

Negative
control

Figure 3.7. Examining the effect of the size of mPEG-SH stabilizer on the cellular binding of
SA-conjugated AuNPs. CD44-biotin was diluted in PBST0.01%. SA:AuNP = 5K:1. (A)
Hydrodynamic size before purification by centrifugation. (B) Hydrodynamic size after
purification by centrifugation. (C) comparison of the size for different formulations before and
after purification by centrifugation. 1: bare AuNPs (both red and black plots are the size of
AuNPs without centrifugation). 2: SA/AuNPs. 3: mPEG-SH2k/AuNPs. 4: mPEG-SH5k/AuNPs.
5: SA/mPEG-SH2K/AuNPs. 6: SA/mPEG-SH5K/AuNPs. (D) Dak field images of MDA-MB231 cells targeting CD44 marker (top row) using SA/AuNPs (left column), SA/mPEGSH2k/AuNPs (middle column), and SA/mPEG-SH5k/AuNPs (right column) with their controls
(bottom row).
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Figure 3.7 D shows the dark field images of CD44-targeting MDA-MB-231 cells labeled
with SA/AuNPs, SA/mPEG2k/AuNPs, and SA/mPEG5k/AuNPs. The results show that both
SA/mPEG2k/AuNPs and SA/mPEG5k/AuNPs showed high bindings to the cells. The
SA/AuNPs showed lower binding than SA/mPEG2k/AuNPs and SA/mPEG5k/AuNPs. This
study suggests that PEGylation helps cellular binding of SA-conjugated AuNPs regardless of the
polymer chain length.

Figure 3.8. Absorption spectrum of CD44-targeting MDA-MB-231 cells after incubation with
mPEG-SH2k/AuNPs (black curve) and SA/mPEG2k/AuNPs (red curve). The presence of
absorption peak around 528 nm suggestions the binding of SA/mPEG2k/AuNPs to the cancer
cells.

The presence of the AuNPs on the cells were further confirmed by absorption spectrum
(Figure 3.8). Using the 5k SA/mPEG2k/AuNPs as the example, we measured the absorption
spectrum in comparison to mEG2k/AuNPs. The LSPR peak of AuNPs around 528 nm suggests
the binding of the conjugates on the cells.
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4. Conclusion
Using SA-conjugated AuNPs, we have shown that cellular labeling largely depends on
the surface chemistry of the particles and the matrix of the binding agents. For the SAconjugated AuNPs, SA-to-AuNPs loading ratio of 5000 or higher is needed to make stable and
monodisperse conjugates for efficient labeling. The conjugates with PEG stabilization were
better than that without PEG. However, the molecular weight of PEG did not play an important
role. SA-conjugated AuNPs stabilized with mPEG-SH 2000 or 50000 showed similar cellular
binding. Tween or BSA was needed to dilute the primary antibody or secondary antibody to
achieve good cellular labeling, with PBST showing better cellular binding than BSA. To dilute
SA-conjugated AuNPs, BSA caused particle aggregation, probably due to biotin impurity in
BSA. Similar to primary or secondary antibody, the PBST0.05% is the best matrix for SAconjugated AuNPs.
It is realized that the optimized SA-AuNP formulation and binding conditions are
concluded from in vitro study alone. For in vivo application, other factors need to be considered,
including stability in blood, organ biodistribution, and tumor uptake. In addition, this study using
spherical nanoparticles as the model. Anisotropic nanoparticles may differ slightly in terms of
ligand density. Thus, future studies with animal models are needed to achieve best proteinnanoparticle conjugates for in vivo applications.
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Chapter 4. DEVELOPMENT OF A GOLD NANOPARTICLE-ENHANCED ENZYMELINKED IMMUNOSORBENT ASSAY FOR DETECTION OF ANTIBODIES AGAINST
SARS-COV-2 SPIKE PROTEIN
1. Introduction
The ongoing coronavirus pandemic (COVID-19) is caused by a pathogen named severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first reported in Wuhan, China in
2019.140-142 Since its onset, the disease has inflicted over 230 million people and caused nearly 5
million deaths worldwide.143 SARS-CoV-2 belongs to the same family of coronaviruses as
severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory
syndrome coronavirus (MERS-CoV).144 The viral particle is spherical in shape and spans 125 nm
in diameter; it includes a single stranded RNA genome and four structural proteins consisting of
a spike protein, membrane protein, envelope protein, and nucleocapsid protein.145 The spike
protein plays a critical role in granting entry of the virus into the host cell by interacting with cell
receptors like the angiotensin converting enzyme 2 (ACE-2).146 The spike protein’s prominent
location outside the viral particle and its critical role in gaining entry of the virus into the host
cell make it an effective target for an immune system response.147
The standard method for detecting active COVID-19 cases is by amplifying and detecting
viral RNA using real-time reverse-transcriptase polymerase chain reaction (RT-PCR) techniques.
To detect SARS-CoV-2 RNA, samples must be obtained from a nasal or pharyngeal swab, or
less commonly a bronchoalveolar lavage sample, as the virus is known to infect the lower
respiratory tract. 141,148-150 RT-PCR-based detection is an established method that offers highthroughput screening, superior sensitivity, and high selectivity. In addition, it is a useful
technique for clinics in discerning active viral cases. However, this detection method does
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present some limitations including a potentially lengthy wait time for results that can span days
to weeks.151 Another limitation is that equipment required for high-throughput RT-PCR detection
must generally be housed in large laboratory facilities. Furthermore, although RT-PCR is a
valuable resource in determining active SARS-CoV-2 cases, this information must be
supplemented with serological testing to determine seroprevalence, evaluate candidates for
monoclonal antibody drugs, as well as to monitor vaccine response.152-154
Serological tests may be used to detect SARS-CoV-2-specific IgG and IgM antibodies
and are considered valid confirmations of infection.155 These tests typically include techniques
such as lateral flow assay, chemiluminescent assays, and enzyme-linked immunosorbent assay
(ELISA). It has been shown that IgM response to SARS-CoV-2 is detectable in the beginning
stages of infection, crossing the detection threshold at day 4 and peaking near day 20 in one
study.156 The immune system’s IgG response is delayed compared to IgM response, as IgM
provides early-stage viral protection and IgG response is dedicated to long-term immunity and
immunological memory.157 In addition to detecting infection, serological testing will be critical
in gauging SARS-CoV-2 vaccine efficacy, especially for populations experiencing an
immunosuppressive illness or undergoing immunosuppressive treatment.158,159 A focus on
developing fast, reliable, economical, and sensitive immunoassays will be of great aid as we
continue to combat the SARS-CoV-2 pandemic.
ELISA is a standard immunoassay capable of detecting and quantifying biological
analytes in a variety of sample matrices.160 In addition to being an agile method, it is also a
sensitive one capable of routinely detecting sub-ng/mL analyte concentrations.161 Since ELISA is
such an established and reliable platform, there have been many important efforts using the
ELISA scheme to design novel, ultra-sensitive assays.162-164 In this study, we endeavor to
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demonstrate a gold nanoparticle (AuNP) enhanced ELISA method for detecting SARS-CoV-2
spike protein IgG antibodies. We combine the reliability of the ELISA scheme with the unique
properties of AuNPs, like a high surface-to-volume ratio and facile surface modification, that
afford our method significantly improved enhancement over standard ELISA. We first optimize
a sandwich ELISA method for specific and effective capture of SARS-CoV-2 spike protein
antibody. This is followed by the design and optimization of anti-IgG/HRP-conjugated AuNPs
for specific and sensitive detection of spike protein antibodies without sacrificing the speed and
reliability of standard ELISA.
2. Materials and Methods
2.1 Materials
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise
specified. Goat anti-mouse IgG/HRP and mouse anti-human CD44 were purchased from
Biolegend (San Diego, CA). SARS-CoV-2 spike protein S1 subunit and SARS-CoV-2 spike
protein S1 subunit IgG antibody were purchased from R&D Systems (Minneapolis, MN).
Thiolated methoxy polyethylene glycol (mPEG-SH, MW = 5000) and thiolated polyethylene
glycol N-hydroxy succinimide (HS-PEG-NHS, MW = 1000) were purchased from Nanocs
(Natick, MA). Dulbecco’s modified Eagle’s medium (DMEM) with high glucose (4.5 g/L),
0.25% trypsin, 100 U/mL HyClone penicillin–streptomycin (P/S), and TMB Plus Liquid 1Component substrate were purchased from VWR (Atlanta, GA). Fetal bovine serum (FBS),
nonessential amino acids (NEAA), beta-propiolactone (BPL) and bovine serum albumin (BSA)
were purchased from Fisher Scientific (Waltham, MA). Gold colloid nanospheres 80 nm were
purchased from BBI solutions (Portland, ME). MDA-MB-231 cell line was purchased from
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ATCC (Manassas, VA). Human blood plasma was isolated from whole blood from healthy
donors purchased from Research Blood Components (Watertown, MA).
2.2 Cell Culture
MDA-MB-231 breast cancer cells were cultured in DMEM with 10% FBS, 1% NEAA,
100 U/mL penicillin, and 0.1 mg/mL streptomycin at 37 °C with 5% CO2. For ELISA
experiments, cells were cleaved from culture dishes using trypsin solution, purified, and 2000
cells per well (in 50 μL medium) were plated in a 96-well cell culture plate and incubated for
24–48 h at 37 °C with 5% CO2.
2.3 Identifying a Compatible Virus Inactivation Method
BPL and formaldehyde (FA) were selected as potential virus inactivation
candidates.165,166 CD44 antibody targeting high expression CD44 receptor on MDA-MB-231
cells was used as the antibody model in preliminary studies. CD44 monoclonal antibody was
diluted in phosphate buffer solution (PBS), cell culture medium, or human plasma (10 times
diluted in PBS) at different concentrations. The antibodies were incubated with different
concentrations of beta-propiolactone (BPL) (0 to 0.1% final concentration) for16 h at 4°C,
followed by 2h incubation at 37°C. Similarly, antibodies were incubated with different
concentrations of formaldehyde (FA) (0 to 4% final concentration) for 1 h at RT. The activities
of the CD44 antibodies with and without BPL treatments, and with and without FA treatments,
were evaluated by characterizing their bindings to CD44 receptors on MDA-MB-231 breast
cancer cells (MDA-MB-231 has high expression of CD44) using an indirect cellular ELISA
assay.167 In this assay, horseradish peroxidase (HRP)-conjugated anti-mouse IgG secondary
binds to CD44 antibody on MDA-MB-231 cells and be detected by 3,3,5,5-tetramethylbenzidine
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solution (TMB) via enzyme-based amplification. Colorimetric signals were recorded at 450 nm.
To compare the antibody activities between different groups, we normalized the signals using the
untreated groups (0% BPL and 0% FA) as the reference (100% activity). When the optimal
reagent was determined for method compatibility, it was tested using our optimized ELISA
method for detection of SARS-CoV-2 anti-S1.
2.4 Optimization of Standard ELISA for SARS-CoV-2 Spike Protein Antibodies
Each parameter of a capture-based sandwich ELISA method was tested for optimal
detection of SARS-CoV-2 anti-S1 IgG. In our optimized procedure, 50 µL of 5 µg/mL SARSCoV-2 spike protein S1 subunit in PBS is used to coat wells of a 96-well plate for 16 h at 4°C.
The S1 subunit solution is removed and followed by gentle washing by PBS three times. Nonspecific binding is then blocked by 100 µL of 1% BSA solution in PBS for 30 minutes at 37°C.
The blocking buffer is removed and followed by three gentle washings with PBS. Next, 50 µL of
various concentrations of anti-S1 IgG in various matrices are incubated in the well for 1 h at
37°C. Anti-S1 IgG is removed followed by 2 washings by PBST (0.05%) and 3 washings by
PBS. Wells are then incubated with 50 µL of 120 ng/mL goat anti-mouse IgG/HRP in 1% BSA
for 1 h at 37°C. Secondary antibody is then removed followed by 2 washings by PBST (0.05%)
and 3 washings by PBS. Next, wells are incubated 100 µL of TMB substrate solution for 30 min
at 37°C. Finally, 100 µL of 0.2 M sulfuric acid are added to each well and the absorbance of
each well was measured at 450 nm using a BioTek ELx800 microplate reader.
2.5 Identification of a Method for AuNP-Enhanced ELISA
Based on the unique surface properties of AuNPs, the possibility of packing significant
amounts of targeting ligand or targeting antibody along with HRP for signal generation onto
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AuNP surface became realized. In effect, this would not change the scheme or technical
difficulty of ELISA as traditional secondary antibody would simply be replaced by AuNPenhanced secondary antibody. Several methods were analyzed to determine which modified
AuNP was capable of delivering the greatest target affinity and specificity along with the highest
signal generation. Some of the methods explored include (1) simultaneous and sequential
addition of thiolated streptavidin (SA-SH) and thiolated horseradish peroxidase (HRP-SH) to
AuNPs, (2) attachment of dibenzocyclooctyne (DBCO)-HRP-SH to AuNP surface, followed by
conjugation of azide-streptavidin to HRP via bioorthogonal click chemistry, and (3) direct
attachment of HRP-conjugated anti-IgG to AuNP surface by thiolation of anti-IgG/HRP and
subsequently reacting with AuNP. Studies showed direct attachment of anti-IgG/HRP to AuNP
surface were the optimal choice for AuNPs with the highest target affinity as well as enzyme
activity. In addition to conjugation method, AuNP size was also evaluated for optimization. To
this end, 40-, 50-, 60-, and 80-nm AuNPs were tested and it was determined anti-IgG/HRPconjugated 80-nm AuNPs provided that greatest HRP activity without sacrificing target affinity.
2.6 Synthesis of anti-IgG/HRP-AuNPs
First, 20 µg anti-IgG/HRP were purified using 10 kDa MWCO centrifugal filter at 13000
RPM for 4 minutes. Anti-IgG/HRP was re-dispersed to 0.4 mg/mL in carbonate/bicarbonate (pH
9) buffer. Next, anti-IgG/HRP solution was gently mixed with HS-PEG-NHS with a molar ratio
of 250 HS-PEG-NHS: anti-IgG/HRP and the mixture was incubated for 2 h at 37°C. After
incubation, 100 µL of 50 mM Tris (pH 8) buffer was added to mixture to quench the reaction.
Next, anti-IgG/HRP-PEG-SH was purified from unbound linker three times using 10 kDa
MWCO centrifugal filter at 13000 RPM for 4 minutes. After each purification, antibody solution
was washed with 200 µL 20 mM HEPES (pH 7). After final purification, anti-IgG/HRP-PEG-SH
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was re-dispersed in HEPES buffer with a concentration of 0.4 mg/mL and mixed with 80 pM
colloidal AuNPs (containing 0.05% Tween-20) using a molar ratio of 2000 anti-IgG/HRP-PEGSH:AuNP. The mixture was vortexed gently for 30 s and incubated for 16 h at 4°C in the dark.
Next, mPEG-SH was added to the mixture with a molar ratio of 30,000 mPEG-SH:AuNP and
gently shaken for 1.5 h at 25°C in the dark. Finally, modified AuNPs were purified three times
by centrifuging at 10,000 RPM for 5 min. Anti-IgG/HRP-PEG-AuNP solution was washed with
PBST between purifications and re-dispersed in PBST after final purification.
2.7 Characterization of IgG-HRP-AuNPs
The optical extinction of AuNPs was characterized by Thermo Scientific SPECTRONIC™ 200
spectrophotometer. The size of anti-IgG/HRP-conjugated AuNPs and unconjugated AuNPs were
characterized by DLS. A TMB assay was performed to confirm the successful conjugation of
anti-IgG/HRP to AuNPs by our conjugation method. Briefly, 100 μL of anti-IgG/HRPconjugated AuNPs were mixed with 25 μL of TMB Plus Liquid 1-Component substrate solution
for 25 min and the color change of the solution was recorded. AuNPs without anti-IgG/HRP
were used as a negative control.
2.8 AuNP-Enhanced ELISA for SARS-CoV-2 Spike Protein Antibodies in PBS and Healthy
Human Blood Plasma
The optimized anti-IgG/HRP-conjugated AuNPs were tested for satisfactory replacement
of standard anti-IgG/HRP secondary antibody using our capture-based sandwich ELISA for
detection of SARS-CoV-2 anti-S1 IgG. Anti-S1 was spiked into a variety of matrices including
PBS, diluted human healthy blood plasma, as well as pure human healthy blood plasma.
Negative controls included the respective sample matrix with no anti-S1 added, while still
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receiving anti-IgG/HRP-conjugated AuNPs. In this manner, a range of anti-S1 concentrations
were tested to determine the linear range and sensitivity of enhanced ELISA method. The plot of
optical density (O.D.) at 450 nm versus the concentration of anti-S1 was fitted linearly using
Microsoft Excel to get the calibration curve. The limit of detection (LOD) for conventional and
enhanced ELISA were evaluated in PBS and human blood plasma. The LOD was calculated
using the formula in eq. 4.1,
𝐿𝑂𝐷 =

3.3×𝑆𝑦𝑥
𝑠

(4.1)

where Syx is the standard error of the predicted y-value for each x-value in the regression, and s is
the slope of the calibration curve. Parameters remained constant between standard and enhanced
ELISA methods for adequate comparison.
3. Results and Discussion
3.1 Effect of Formaldehyde on CD44 Antibody Activity by Determining Their Binding to CD44
Receptor on MDA-MB-231 Breast Cancer Cells
Figure 4.1 and Table 4.1 show a comparison of the CD44 antibody activity after
incubation with FA of different concentrations. The results show that the activity significantly
decreased after FA treatments for all tested FA concentrations. When the antibody was treated
with 0.5% FA (the concentration that has shown to cause complete virus inactivation), the
antibody activity decreased by 14%, 27%, 35% for 2 µg/mL, 1 µg/mL, and 0.5 µg/mL CD44
antibody, respectively. Increasing FA concentrations further reduced antibody activity.
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A

B

C

Figure 4.1 Normalized antibody activity after FA treatment with different concentrations. (A) 2
µg/mL CD44 antibody. (B) 1 µg/mL CD44 antibody. (C) 0.5 µg/mL CD44 antibody. All
treatments were performed in PBS.

Table 4.1: Effect of formaldehyde on CD44 antibody activity to their binding to CD44 receptor
on MDA-MB-231 breast cancer cells.
Concentration of formaldehyde
Concentration of
CD44 antibody
2 µg/mL

0%

0.5%

1%

2%

4%

1006.1%

86.06.3% 65.22.6%

28.41.3%

6.50.2%

1 µg/mL

1000.9%

73.42.6% 47.51.8%

17.10.2%

8.64.0%

0.5 µg/mL

1005.7%

64.81.8% 36.81.4%

11.70.8%

6.60.2%

3.2 Effect of beta-Propiolactone on CD44 Antibody Activity by Determining Their Binding to
CD44 Receptor on MDA-MB-231 Breast Cancer Cells
Figure 4.2 A shows a comparison of the CD44 antibody activity after incubation with
BPL of different concentrations in PBS at a concentration of 2 µg/mL. As listed in Table 4.2, the
activity slightly decreased to 96% after treatment with 0.0125% BPL, the concentration that
caused complete virus inactivation. Further increase of the BPL concentration led to more
activity reduction, with 0.025% BPL to 91%, 0.05% BPL to 88.7% and 0.1% BPL to 72.6%.
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Since antibody concentration varies as the infection goes on, we need to examine whether the
effect of BPL treatment depends on the antibody concentration. Figure 4.2 B shows the BPL
effect of CD44 antibody at 1 µg/mL and Figure 4.2 C shows the effect of CD44 antibody at 0.5
µg/mL. The results show that the adverse effect of BPL increased when the concentration of
antibody decreased. For example, the treatment of 1 µg/mL CD44 antibody with 0.0125% BPL
reduced the antibody activity by 12% while treatment of 0.5 µg/mL CD44 antibody with
0.0125% BPL reduced the antibody activity by 18%.

A

B

C

Figure 4.2. Normalized antibody activity after BPL treatment with different concentrations of
BPL for different concentrations of antibodies. (A) 2 µg/mL CD44 antibody. (B) 1 µg/mL CD44
antibody. (C) 0.5 µg/mL CD44 antibody. All treatments were performed in PBS.

To further examine the matrix effect, we diluted CD44 antibody in cell culture medium
and 10x diluted (with PBS) human plasma using 0.5 µg/mL CD44 antibody as the model. The
results show that the adverse effect of BPL to antibody activity is significantly lower when the
treatment was performed in 10x diluted plasma than the treatments in PBS and cell culture
medium (Figure 4.3). For the treatment with 0.0125% BPL in the 10x diluted plasma, the
antibody activity decreased by 8%, in contrast to 18% in PBS and 16% in medium.
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A

B

C

Figure 4.3 Normalized antibody activity after BPL treatment with different concentrations of
BPL for antibodies diluted in different matrix. (A) PBS. (B) cell culture medium. (C) 10 times
PBS-diluted human plasma.

To measure the effect of BPL on antibody activity in plasma directly, we diluted CD44
antibody in human plasma (without dilution) in the presence of 0.0125% BPL. Three antibody
concentrations were examined: 0.5 µg/mL, 0.1 µg/mL, and 0.05 µg/mL. The results (Figure 4.4
and Table 4.2) show that the antibody activity reduced by 7%, 16%, and 19% for 0.5 ug/mL, 0.1
ug/mL, and 0.05 ug/mL, respectively. BPL reduced the antibody activities for all tested
concentrations of BPL and antibodies. The adverse effect increased when the concentration of
antibodies decreases. At the lowest concentration of BPL (0.0125%) for virus complete
inactivation, the mildest effect was the treatment of antibody in 10x diluted plasma.

Figure 4.4 Normalized antibody activity of different concentrations anti-CD44 after treatment
with 0.0125% BPL in plasma.
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The antibody activity decreased by 8% when 0.5 µg/mL CD44 antibody was treated with
0.0125% BPL in 10x diluted plasma. When BPL treatment was performed in plasma directly, the
antibody activity decreased by 7% for 0.5 µg/mL CD44 antibody, 16% for 0.1 µg/mL CD44
antibody, and 19% for 0.05 µg/mL CD44 antibody. This indicates that at low antibody
concentrations (≤0.1 ug/mL), the BPL effect is significant and may not be ignored.
Table 4.2: Effect of BPL on CD44 antibody activity to their binding to high expression CD44
receptor on MDA-MB-231 breast cancer cells.
Concentration of BPL
Concentration of
CD44 antibody

0%

0.00625%

0.0125%

0.025%

0.05%

0.1%

2 µg/mL in PBS

1001.6%

94.81.1%

96.22.6%

91.30.6%

88.71.6%

72.62.7%

1 µg/mL in PBS

1005.1%

92.23.6%

88.61.0%

78.83.2%

81.21.0%

45.22.0%

0.5 µg/mL in PBS

1002.9%

89.41.9%

81.92.5%

69.83.4%

78.96.5%

31.72.0%

0.5 µg/mL in cell
culture medium

1003.4%

79.63.7%

84.81.4%

68.82.5%

65.95.3%

53.81.53%

0.5 µg/mL in 10x
diluted human plasma

1005.3%

95.51.18%

91.62.5%

86.94.72%

85.14.3%

81.71.9%

0.5 µg/mL in plasma

1001.0%

-

92.70.8%

-

-

-

0.1 µg/mL in plasma

1005.1%

-

83.91.5%

-

-

-

0.05 µg/mL in plasma

1001.7%

-

81.13.2%

-

-

-

3.3 Effect of beta-Propiolactone on anti-S1 Activity by Determining Their Binding to S1 Subunit
in Sandwich ELISA
When the deteriorating effect of BPL on antibodies was thoroughly modeled using antiCD44, it became necessary to treat SARS-CoV-2 anti-S1 IgG with BPL as a complete simulation
of the effect our targeted analyte will undergo during virus inactivation. Anti-S1 was incubated
with 0.0125% BPL in pure human blood plasma using low concentrations of antibody. It was
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determined that 0.01 µg/mL anti-S1 experienced a 10% decrease in activity, and 0.02 µg/mL
anti-S1 experienced a 3% decrease in activity upon treatment with BPL (Figure 4.5). The
decrease in antibody activity is expected following our studies with anti-CD44, but the effect is
less pronounced when treating anti-S1. This may be due to differences between our cellular
ELISA for detecting anti-CD44 compared to our sandwich ELISA for detecting anti-S1, or
maybe due to differences in the two antibodies. However, this study confirms that 0.0125% BPL,
while mildly affecting antibody activity, is a virus inactivation agent that is compatible with our

Normalized Antibody Activity (%)

detection assay.
120
100
80
60
40
20
0
0.01 ug/mL

0.02 ug/mL

Concentration of Anti-S1
without BPL

with 0.0125% BPL

Figure 4.5 Normalized antibody activity of different concentrations of anti-S1 after treatment
with 0.0125% BPL in plasma.

3.4 Optimization of Sandwich ELISA for Detection of Anti-S1
To qualify the improvement of our enhanced ELISA method over the standard ELISA
technique, each parameter of the standard sandwich ELISA was calibrated for optimal detection
of anti-S1. First, the coating concentration of capture protein, SARS-CoV-2 spike protein S1
subunit, was varied from 1 to 10 µg/mL. As seen in Figure 4.6 A, there is a rapid incline in the
detection sensitivity of this assay from 1 to 5 µg/mL S1 coating concentration. 5 µg/mL S1 was
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selected as the optimal coating concentration for maximizing detection sensitivity as well as
reagent life, as there is only a 7% increase in detection sensitivity from 5 to 10 µg/mL. AntiIgG/HRP was titrated between 1:2000 and 1:5000 upon manufacturer’s recommendation to
determine optimal conditions and 1:3400 dilution, or 120 ng/mL, of anti-IgG/HRP was selected
for generating the highest signal-to-noise ratio. TMB substrate was incubated with 1 and 2
ng/mL anti-IgG/HRP and the reaction was stopped at time points from 1 to 120 min. From
Figure 4.6 B, it is apparent most of the signal is generated in the first 30 minutes of the reaction.
The optimal incubation time for HRP/TMB reaction was selected to be 30 min for obtaining
maximum detection sensitivity without drastically lengthening the assay time.
The detection capability of the optimized sandwich ELISA was tested for sensitivity to
SARS-CoV-2 anti-S1 IgG. To determine the limit of detection (LOD) for this assay, anti-S1 was
spiked into PBS as well as pure human healthy blood plasma at concentrations from 0.5 to 20
ng/mL, as seen in Figure 4.6 C-D. The LOD of our optimized standard ELISA for anti-S1 in PBS
was determined to be 3.7 ng/mL. In plasma samples, the LOD was determined to be 1.1 ng/mL.
Although detecting anti-S1 in plasma generates substantially higher signals than for PBS, the
negative controls gave comparable signals for the two different matrices. The background signal
for anti-S1-containing plasma was 26% higher compared to PBS samples, likely due to crossreactivity between the secondary antibody and components in the plasma. The calibration curves
in these assays show a good fit to the data with coefficients of determination of 0.983 and 0.995
in PBS and plasma, respectively.
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Figure 4.6 Optimization of standard ELISA method for detection of SARS-CoV-2 spike protein
IgG. (A) Determination of optimum spike protein S1 subunit coating concentration for capture of
spike protein antibody. (B) Optimizing the TMB reaction by incubating with 1 ng/mL and 2
ng/mL IgG-HRP solution. Determining the sensitivity of standard ELISA for detecting SARSCoV-2 spike protein antibody in PBS (C) and healthy human blood plasma (D).

3.5 Design of the AuNP-Enhanced ELISA
Sandwich ELISA is an established method for selective capture and sensitive detection of
biological analytes through serology testing. Since the method is widely employed, it is
conceivable to build on our understanding and infrastructure and design novel methods for
sensitive detection using ELISA as a template. We selected AuNPs as a mode by which we can
amplify standard ELISA detection based on the unique surface properties of AuNPs.168 For one,
their nm-range size imparts compatibility for interacting with like-sized bio-analytes.
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Additionally, they exhibit high surface-to-volume ratios critical for delivering maximum
amounts of probing molecules. Furthermore, they display a chemically reactive surface that may
be readily functionalized with targeting biomolecules. For these reasons, we elected to use IgGtargeted AuNPs to deliver large amounts of HRP near analyte for the sensitive detection of
SARS-CoV-2 anti-S1 IgG. Figure 4.7 shows a comparison between the two detection schemes of
standard ELISA and AuNP-enhanced ELISA.

Figure 4.7 A schematic representation of standard ELISA (left) method compared to AuNPenhanced ELISA (right) method for detection SARS-CoV-2 spike protein antibodies.

3.6 Application of AuNP-Enhanced ELISA for Detecting SARS-CoV-2 anti-S1
We applied our enhanced ELISA technique to PBS and human blood plasma samples
with anti-S1 spiked in as seen in Figure 4.8. The technique remained identical to standard ELISA
technique except for the replacement of standard secondary antibody, anti-IgG/HRP, by our antiIgG/HRP-conjugated AuNP. In PBS, we see a significant improvement in sensitivity over
standard ELISA with an LOD of 18.0 pg/mL and a similar coefficient of determination, 0.986. In
pure human blood plasma, we observe a marked improvement over standard ELISA, but with a
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higher LOD, 370.5 pg/mL, than we experience for enhanced ELISA in PBS. It is also observed
that AuNP-enhanced ELISA generates a higher background signal than standard ELISA. The
effect is especially exaggerated in pure plasma. However, we determined that the exaggerated
background subsides as plasma is further diluted, indicating the utility of this method for
determining the antibody titer in serology testing.

B
0.6

3.5

0.5

3
2.5

0.4

O.D. (450 nm)

O.D. (450 nm)

A

0.3
y = 0.0028x + 0.2177
0.2
R² = 0.9864
0.1

2

y = 0.0013x + 2.006

1.5
R² = 0.9119
1
0.5
0

0
0

20

40

60

80

100

0

120

[IgG] pg/mL

200

400

600

800

1000

1200

[IgG] (pg/mL)

Figure 4.8 Determining the sensitivity of AuNP-enhanced ELISA for detecting SARS-CoV-2
spike protein IgG in (A) PBS and (B) healthy human blood plasma through a series of spike-in
experiment. Although AuNP-enhanced method does generate significantly more background
than standard ELISA, the limit of detection is significantly lower for enhanced method.

4. Conclusion and Future Outlook
In this study, we demonstrated the ability to use AuNPs in an effort to enhance ELISA
for the detection of SARS-CoV-2 anti-S1 IgG. We used AuNPs’ high surface-to-volume ratio
and surface reactivity to efficiently load their surface with HRP and targeting antibody. This
method significantly improves the sensitivity of standard ELISA by as much as 200-fold in PBS
without increasing the difficulty and time of the assay. We intend to continue the development of
this method by applying it to SARS-CoV-2-infected mouse sera in a collaboration with Dr. Kui
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Li of University of Tennessee Health Science Center in Memphis, TN. In this collaboration we
seek not only to prove the sensitivity of this enhanced assay, but to gain an understanding of
virus-host interactions through real-time monitoring of serum in mouse models.
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Chapter 5. CONCLUSION AND FURTHER PERSPECTIVES
In this dissertation, we have provided an overview of the history of AuNPs. Furthermore,
we have discussed some of the important qualities of AuNPs that make them so useful in the
biomedical field. For one, they are extremely biocompatible, especially when coated with a
protective layer such as PEG. Next, they possess excellent loading capacity due to their high
surface-to-volume ratio, as well as an easily modified surface allowing functionalization by any
number of thiolated molecules. Finally, AuNPs provide superior optical enhancement through
the nanoscale phenomenon of localized surface plasmon enhancement. This phenomenon is
especially applicable in surface-enhanced Raman scattering spectroscopy enabling single
molecule and single particle detection. These properties have allowed researchers to develop
some very creative methods for detecting analytes. From metal ions to cancer cells, AuNPs have
shown to be a great asset in the field of circulating biomarker detection.
In Chapter 2, we have shown that IO-Au core-shell SERS nanotags can serve a dual
function of selectively isolating and detecting CTCs from human whole blood in a microfluidic
device. Multicolor SERS nanotags were first realized by the addition of select Raman reporters
and targeting ligands to IO-Au core-shell nanoparticles. The multicolor SERS nanotags were
then capable of targeting four distinct cancer markers. Furthermore, we showed that distinct
Raman signals corresponding to expression of EpCAM, HER2, CD44, and IGF1R could be
obtained from a signal mixture by using CLS deconvolution. The cancer marker expression
profiles obtained using our method were compared to ELISA profiles as a reference. This
comparison suggests that our method has the potential to simultaneously detect CTCs of multiple
subpopulations in clinical samples. In our method, all cell isolation/enrichment, negative
staining, optical imaging, SERS detection, and molecular profiling were performed on a
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microfluidic device. This device increases the degree of operational automation, enables singlecell analysis, and reduces false negative signals by concentrating low-frequency tumor cells. We
connect isolation and detection methods with multiplex IO−Au SERS nanotags, making the
sample preparation simple and easy to operate. CTC identification is based on a combination of
several characteristics at the single-cell level. First, we confirm the morphological standards of
suspected cancer cells through bright-field imaging. We then determine if any blood cell
impurities are present through fluorescence staining and imaging. Finally, molecular cancer cell
detection is ascertained through SERS. The combination of these criteria reduces false positives
and ensures detection accuracy. In this manner, a simple, sensitive, and selective method for
capture and multicolor detection of CTCs from whole blood is provided.
In Chapter 3, we used ligand-conjugated AuNPs to show that cellular labeling largely
depends on the surface chemistry of the particles and the matrix conditions during binding.
Thiolated SA was used as a ligand model to show that loading ratio of 5000 or higher is needed
to make stable conjugates with uniform size distribution for efficient labeling. We also
determined that SA-AuNPs stabilized with a PEG layer were better for cellular labeling than SAAuNPs without PEG. Interestingly, the molecular weight of PEG did not play an important role
in stabilizing the conjugates. When comparing mPEG-SH 2000 and 5000, both PEG-stabilized
conjugates showed similar cellular binding. In addition to particle formulation, the matrix
conditions for cellular labeling were analyzed for optimal binding potential. We determined that
Tween (in PBS) or BSA (in PBS) was necessary for primary and secondary antibody dilution,
with antibodies in PBST showing better binding potential than in BSA. We also determined the
optimal storage and binding conditions for SA-conjugated AuNPs. We observed that SA-AuNPs
stored with BSA experienced particle aggregation, likely due to biotin impurity in BSA. Similar
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to primary and secondary antibody conditions, it was shown that PBST provided the best storage
and labeling conditions for SA-AuNPs. In this chapter, we have surveyed ligand-conjugated
AuNP formulation and cellular labeling matrix conditions with the aim of providing robust
techniques to achieve optimal cellular binding results.
In Chapter 4, we sought to use the unique surface properties of AuNPs in order to
enhance the sensitivity of conventional ELISA for detecting SARS-CoV-2 spike protein
antibody. We utilized the facile surface modification and high surface area-to-volume ratio
characteristic of AuNPs to load HRP-conjugated anti-IgG onto particle for colorimetric detection
of primary antibody. We optimized the formulation of these IgG/HRP-conjugated AuNPs for
selectively recognizing anti-S1 IgG in PBS or human blood plasma. This method for enhancing
conventional ELISA was determined to be over 200 times more sensitive than conventional
ELISA when analyte is contained in PBS. Substantial background signal was detected when
analyte was contained in pure plasma, however, this background is readily overcome by diluting
plasma samples with PBS. We intend to continue the development of this method by testing
SARS-CoV-2-infected mouse blood serum in collaboration with Dr. Kui Li of University of
Tennessee Health Science Center in Memphis, TN. We aim to demonstrate the capability of this
method for detecting rare IgG in infected mouse serum as well as to better understand virus-host
interactions through real-time monitoring of serum in mouse models.
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APPENDIX A
Table S1. Determination of the number of proteins per IO-Au NPC with Micro BCA protein
assay.
Amount IgG added to conjugation
Amount bound (ug)
(ug)

Ab/NPC

5

1.4

4.7

10

9.44

31.8

20

14.21

47.4

Table S2. Examination of the accuracy of multicolor IO-Au SERS nanotags with CLS regression
for multiplexed detection.
Mixed Ratio of
QSY21:BHQ3:
QXL680:IR740

1111

2111

1311

1141

1115

2345

Experimental
0.236502948
0.26588259
0.257546386
0.247482829
0.400094125
0.185291997
0.212525256
0.20075023
0.163686839
0.490893207
0.1846922
0.178730002
0.154900746
0.131196028
0.588325069
0.157753279
0.137975157
0.116596447
0.121817743
0.619511494
0.139289609
0.216368292
0.282536933
0.359550751

Expected
0.25
0.25
0.25
0.25
0.4
0.2
0.2
0.2
0.166666667
0.5
0.166666667
0.166666667
0.142857143
0.142857143
0.571428571
0.142857143
0.125
0.125
0.125
0.625
0.142857143
0.214285714
0.285714286
0.357142857
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δ
5.398820723
6.353035851
3.01855457
1.006868461
0.023531217
7.354001352
6.262628225
0.375115209
1.787896342
1.821358626
10.81532013
7.238001449
8.430521942
8.162780345
2.956887146
10.42729543
10.3801257
6.722842056
2.545805284
0.878160947
2.497273372
0.971869436
1.112073281
0.674210415

% Accuracy
94.60117928
93.64696415
96.98144543
98.99313154
99.97646878
92.64599865
93.73737178
99.62488479
98.21210366
98.17864137
89.18467987
92.76199855
91.56947806
91.83721966
97.04311285
89.57270457
89.6198743
93.27715794
97.45419472
99.12183905
97.50272663
99.02813056
98.88792672
99.32578959

Figure S1. Dark field images of SK-BR-3 cells after incubation with IO-Au core-shell NPCs
with different amount of loading antibody. (A) to (D) is 2.5, 5, 10, and 20 uL of 1 mg/mL
antibody, respectively, to 0.25 mL of 1 nM IO-Au SERS NPCs.
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Figure S2. Characterization of the bound proteins on IO-Au NPCs by measuring absorbance at
562 nm in the Micro BCA protein assay. IgG was used as the protein model.

109

Figure S3. Examination of the stability of SERS nanotags in blood. SERS signal intensities were
measured at 1497 cm-1 for QSY21, 1092 cm-1 for BHQ3, 1139 cm-1 for QXL680, and 501 cm-1
for IR740. They were normalized to the highest intensity among the groups for each nanotag.
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Figure S4. Characterization of EpCAM, HER2, CD44, and IGF1R expressions on SK-BR-3,
MDA-MB-231, and MCF-7 cells with flow cytometry.
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Figure S5. Signal deconvolution with CLS regression. (A) The CLS module showing the step of
loading the reference spectra of the 4 color SERS nanotags. (B) The CLS module showing the
step of signal deconvolution of each nanotag from the mixed SERS spectrum.
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